Author: "Buhl Roland" / Database: OpenAIRE - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Buhl Roland"' showing total 60 results

Start Over Author "Buhl Roland" Database OpenAIRE

60 results on '"Buhl Roland"'

1. The German Asthma Net: Anti-IL5(R) therapy reduces disease burden in a real-life severe asthma cohort in comparison to patients on maintenance OCS therapy

Author: Bal, Christina, Korn, Stephanie, Milger, Katrin, Skowasch, Dirk, Schulz, Christian, Zehetmayer, Sonja, Taube, Christian, Hamelmann, Eckard, Buhl, Roland, and Idzko, Marco
Subjects: Medizin
Published: 2023

2. The German Asthma Net: Anti-IL5(R) therapy reduces disease burden in a real-life severe asthma cohort

Author: Bal, Christina, Idzko, Marco, Milger, Katrin, Skowasch, Dirk, Schulz, Christian, Taube, Christian, Hamelmann, Eckard, Buhl, Roland, and Korn, Stephanie
Subjects: Medizin
Abstract: Introduction: 718 of 2283 patients with severe asthma included in the real-life, long-term German Asthma Net (GAN) registry used anti-IL5(R) antibody therapy (mepolizumab, benralizumab, reslizumab), of which 343 had started therapy after registry inclusion (56±13 yrs., 55% female, 1.7% current smokers, mean BMI 27±5 kg/m², 4.6±4.6 exacerbations per year, ACQ score 2.9±1.4). Results: In comparison to baseline, patients on anti-IL5(R) therapy showed significantly less exacerbations (rate reduction (mean±SD) at year 1: -3.0±5.3, p
Published: 2023

3. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update

Author: Levy, Mark L, Bacharier, Leonard B, Bateman, Eric, Boulet, Louis-Philippe, Brightling, Chris, Buhl, Roland, Brusselle, Guy, Cruz, Alvaro A, Drazen, Jeffrey M, Duijts, Liesbeth, Fleming, Louise, Inoue, Hiromasa, Ko, Fanny WS, Krishnan, Jerry A, Mortimer, Kevin, Pitrez, Paulo M, Sheikh, Aziz, Yorgancıoğlu, Arzu, Reddel, Helen K, Levy, Mark L [0000-0002-1807-3246], Bateman, Eric [0000-0002-5064-5849], Boulet, Louis-Philippe [0000-0003-3485-9393], Fleming, Louise [0000-0002-7268-7433], Inoue, Hiromasa [0000-0001-8080-3812], Ko, Fanny W S [0000-0001-8454-0087], Krishnan, Jerry A [0000-0001-5525-4778], Mortimer, Kevin [0000-0002-8118-8871], Pitrez, Paulo M [0000-0001-7319-1133], Yorgancıoğlu, Arzu [0000-0002-4032-0944], Reddel, Helen K [0000-0002-6695-6350], Apollo - University of Cambridge Repository, and Ko, Fanny WS [0000-0001-8454-0087]
Subjects: Adult, Pulmonary and Respiratory Medicine, Adolescent, Primary Health Care, Anti-Asthmatic Agents/therapeutic use, Public Health, Environmental and Occupational Health, Adrenal Cortex Hormones/therapeutic use, Asthma/diagnosis, Asthma, SDG 3 - Good Health and Well-being, Adrenal Cortex Hormones, Formoterol Fumarate, Administration, Inhalation, Humans, Anti-Asthmatic Agents, Child, Formoterol Fumarate/therapeutic use
Abstract: The Global Initiative for Asthma (GINA) was established in 1993 by the World Health Organization and the US National Heart Lung and Blood Institute to improve asthma awareness, prevention and management worldwide. GINA develops and publishes evidence-based, annually updated resources for clinicians. GINA guidance is adopted by national asthma guidelines in many countries, adapted to fit local healthcare systems, practices, and resource availability. GINA is independent of industry, funded by the sale and licensing of its materials. This review summarizes key practical guidance for primary care from the 2022 GINA strategy report. It provides guidance on confirming the diagnosis of asthma using spirometry or peak expiratory flow. GINA recommends that all adults, adolescents and most children with asthma should receive inhaled corticosteroid (ICS)-containing therapy to reduce the risk of severe exacerbations, either taken regularly, or (for adults and adolescents with “mild” asthma) as combination ICS–formoterol taken as needed for symptom relief. For patients with moderate–severe asthma, the preferred regimen is maintenance-and-reliever therapy (MART) with ICS–formoterol. Asthma treatment is not “one size fits all”; GINA recommends individualized assessment, adjustment, and review of treatment. As many patients with difficult-to-treat or severe asthma are not referred early for specialist review, we provide updated guidance for primary care on diagnosis, further investigation, optimization and treatment of severe asthma across secondary and tertiary care. While the GINA strategy has global relevance, we recognize that there are special considerations for its adoption in low- and middle-income countries, particularly the current poor access to inhaled medications.
Published: 2023

4. [Untitled]

Author: Lommatzsch, Marek, Criée, Carl-Peter, de Jong, Carmen C M, Gappa, Monika, Geßner, Christian, Gerstlauer, Michael, Hämäläinen, Nina, Haidl, Peter, Hamelmann, Eckard, Horak, Fritz, Idzko, Marco, Ignatov, Atanas, Koczulla, Andreas Rembert, Korn, Stephanie, Köhler, Michael, Lex, Christiane, Meister, Jochen, Milger-Kneidinger, Katrin, Nowak, Dennis, Nothacker, Monika, Pfaar, Oliver, Pohl, Wolfgang, Preisser, Alexandra M, Rabe, Klaus F, Riedler, Josef, Schmidt, Olaf, Schreiber, Jens, Schuster, Antje, Schuhmann, Maren, Spindler, Thomas, Taube, Christian, Christian Virchow, Johann, Vogelberg, Christian, Vogelmeier, Claus Franz, Wantke, Felix, Windisch, Wolfram, Worth, Heinrich, Zacharasiewicz, Angela, and Buhl, Roland
Subjects: 610 Medicine & health
Abstract: The management of asthma has fundamentally changed during the past decades. The present guideline for the diagnosis and treatment of asthma was developed for respiratory specialists who need detailed and evidence-based information on the new diagnostic and therapeutic options in asthma. The guideline shows the new role of biomarkers, especially blood eosinophils and fractional exhaled NO (FeNO), in diagnostic algorithms of asthma. Of note, this guideline is the first worldwide to announce symptom prevention and asthma remission as the ultimate goals of asthma treatment, which can be achieved by using individually tailored, disease-modifying anti-asthmatic drugs such as inhaled steroids, allergen immunotherapy or biologics. In addition, the central role of the treatment of comorbidities is emphasized. Finally, the document addresses several challenges in asthma management, including asthma treatment during pregnancy, treatment of severe asthma or the diagnosis and treatment of work-related asthma., Das Management von Asthma hat sich in den letzten Jahrzehnten fundamental gewandelt. Die vorliegende Leitlinie zur Diagnostik und Therapie von Asthma wurde für pneumologisch tätige Fachärztinnen und Fachärzte entwickelt, welche detaillierte und evidenzbasierte Informationen zu den neuen diagnostischen und therapeutischen Optionen von Asthma benötigen. Die Leitlinie zeigt die neue Bedeutung der Biomarker, insbesondere der Bluteosinophilen und des exhalierten NO (FeNO), in den diagnostischen Algorithmen von Asthma. Als erste Asthma-Leitlinie weltweit benennt die vorliegende Leitlinie die nachhaltige Symptomprävention und die Asthma-Remission als Asthma-Therapieziele, welche durch den Einsatz individuell angepasster, krankheitsmodifizierender Medikamente (wie inhalative Steroide, Allergenimmuntherapie oder Biologika) erreicht werden können. Die zentrale Bedeutung der Behandlung von typischen Asthma-Komorbiditäten wird zudem betont. Schließlich wird auch auf besondere Herausforderungen im Asthma-Management eingegangen, wie bspw. die Therapie von Asthma in der Schwangerschaft, die Behandlung von schwerem Asthma oder die Diagnostik und Therapie von arbeitsbedingten Asthma-Formen.
Published: 2023
Full Text: View/download PDF

5. Rhinitis associated with asthma is distinct from rhinitis alone: TARIA‐MeDALL hypothesis

Author: Bousquet, Jean, Melén, Erik, Haahtela, Tari, Koppelman, Gerard, Togias, Alkis, Valenta, Rudolf, Akdis, Cezmi, Czarlewski, Wienczyslawa, Rothenberg, Marc, Valiulis, Arunas, Wickman, Magnus, Vichyanond, Pakit, Moniuszko, Marcin, Ėmužytė, Regina, Bush, Andrew, Chu, Derek K, Viegi, Giovanni, Wallace, Dana, Durham, Stephen, Wang, De Yun, Vandenplas, O., Just, Jocelyne, Carlsen, Karin C. Lodrup, Passalacqua, Giovanni, Williams, Siân, Linnemann, Désirée Larenas, Loureiro, Cláudia Chaves, Sagara, Hironori, Worm, Margitta, Yiallouros, Panayiotis, Yusuf, Osman, Zaitoun, Fares, Bonini, Matteo, Hrubiško, Martin, Cingi, C., Dykewicz, Mark, Zernotti, Mario, Calderon, Moises, Halpin, David M.G., Zidarn, Mihaela, Patella, Vincenzo, Sheikh, Aziz, Zuberbier, Jaron, Papadopoulos, Nikolaos, Louis, Renaud, Suppli Ulrik, Charlotte, Fonseca, João P., Zuberbier, Torsten, Anto, M. J., Costa, Elisio, Eiwegger, Thomas, Bosnic-Anticevich, Sinthia, Cruz, Alvaro, Sousa, Jaime Correia de, Louis-Philippe, Boulet, Erhola, Marina, Cardona, Victoria, Carr, Warner, Gemicioglu, Bilun, Pawankar, Ruby, Fokkens, Wytske, Calvo, Mário, Garcia-Aymerich, J., Mäkelä, Mika J., Hofmann, Maja Ann, Klimek, Ludger, Makris, Michael, Mohamed Sayed, Zeinab, Maurer, Marcus, D'Amato, G., Momas, Isabelle, Siroux, Valérie, Almeida, Mário Morais, Corrigan, Chris, Mullol, Joaquim, Montefort, Stephen, Jutel, Marek, Pham Thi, Nhan, Hossny, Elham, Akdis, Mubeccel, Pfaar, Oliver, Ventura, Maria Teresa, Regateiro, Frederico S., Bindslev-Jensen, Carsten, Ring, Johannes, Bustamante, Mariona, Pinto, Bernardo Sousa, Kaidashev, Igor, Guerra, Stefano, Standl, Marie, Sunyer, J., Keil, Thomas, Barata, Luís Taborda, Camargos, Paulo, Weiss, Scott, Naclerio, Robert, Yorgancıoglu, Arzu, Zhang, Luo, Nadeau, Kari, Abdul Latiff, Amir, Aberer, Werner, Heinrich, Joachim, Sisul, Juan, Nunes, Elizabete, Plavec, Davor, Agache, Ioana, Al-Ahmad, Mona, Serpa, Faradiba, Alobid, Isam, Kalayci, Omer, Giacco, S. Del, Fiocchi, Alessandro, Ansotegui Zubeldia, Ignacio Javier, Custovic, Adnan, Martins, Pedro Carreiro, Rouadi, Philip, Arshad, Syed Hasan, Asayag, Estrella, Bárbara, Cristina, Abdullah, Baharudin, Tomazic, Peter Valentin, Popov, T. A., Sayah, Zineb, Lkhagvaa, Battur, Nyembue Tshipukane , Dieudonne, Thomas, Mike, Bennoor, Kazi Saifuddin, Fyhrquist, Nanna Theresia, Irani, Carla, Berghea, Elena Camelia, De Blay, Frédéric, Toppila-Salmi, Sanna Katriina, Bergmann, Karl-Christian, Bernstein, D., Bewick, M., Casale, Thomas, Scheire, Sophie, Bumbacea, Roxana Silvia, Cepeda Sarabia, Alfonso, Puggioni, Francesca, Chandrasekharan, Ramanathan, Ohta, Ken, Okubo, Kimihiro, Charpin, Denis, Gomez, R Maximiliano, Chen, Y. Z., O'Hehir, Robyn, Cherrez Ojeda, Ivan, Bedbrook, Anna, To, Teresa, Devillier, Philippe, Schmid-Grendelmeier, Peter, Didier, Alain, Repka-Ramirez, María Susana, Teixeira, Maria Do Céu, Ispayeva, Zhanat, Dokic, Dejan, Quirce, Santiago, Douagui , Habib, Ivancevich, Juan Carlos, Gotua, Maia, Todo-Bom, Ana, Blain, Hubert, Guzman, Maria Antonieta, Kalyoncu, Ali Fuat, Hagemann, Jan, Buhl, Roland, Hamamah, Samir, Caraballo, Luis, Jares, Edgardo, Chivato, Tomás, Jartti, Tuomas, Jassem, Ewa, Christoff, George, Julge, Kalev, Ogulur, Ismail, Kardas, Przemyslaw, Doulaptsi, Maria, Kirenga, Bruce, Helga, Kraxner, Kull, Inger, Kulus, Marek, Daniel, Aguilar, Shamji, Mohamed, Kuna, Piotr, Nadif, Rachel, La Grutta, Stefania, Brightling, Chris, Samoliński, Bolesław, Lau, Susanne, Cordeiro, Carlos Manuel Da Silva Robalo, Solé, Dirceu, Le Thi Tuyet, Lan, Recto, Marysia, Ouedraogo, Solange, Halken, Susanne, Levin, Michael, Lipworth, Brian, Lourenço, Olga, Mahboub, Bassam, Niedoszytko, Marek, Sastre, Joaquin, Martinez‐Infante, E., Kupczyk, Maciej, Torres, María Jose, Matricardi, Paolo Maria, Cecchi, Lorenzo, Celedón, Juan C, Miculinic, Neven, Roche, Nicolas, Migueres, Nicolas, Brussino, Luisa, Florin, Mihaltan, Olze, Heidi, Savouré, Marine, Nekam, Kristof, Pali, Isabella, Okamoto, Yoshitaka, Palomares, O., Lemonnier, Nathanaël, Palosuo, Kati, Soto-Martinez, Manuel, Panaitescu, Carmen, Kvedarienė, Violeta, Panzner, P., Braido, Fulvio, Tsiligianni, Ioanna, Rodriguez-Gonzalez, Monica, Scichilone, Nicola, Canonica, Giogio Walter, Romantowski, Jan, Urrutia-Pereira, Marilyn, Filho, Nelson Augusto Rosario, Ollert, Markus W., Rottem, Menachem, Chkhartishvili, Ekaterine, Sova, Milan, Valovirta, Erkka, Mohammad, Yousser, Sperl, Annette, Spranger, Otto, Neffen, Hugo, Stelmach, Rafael, Burte, Emilie, Valentin Rostan, Marylin, Park, Hae-Sim, Van Ganse, Eric, Van Hage, Marianne, Pitsios, Constantinos, Vasankari, Tuula, and uBibliorum
Subjects: IL-33, Multimorbidity, Asthma, Toll-like receptors, Rhinitis
Abstract: Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one-airway-one-disease,” coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one-airway-one-disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis.
Published: 2023

6. Recommendations for use of topical inhalant budesonide in COVID-19

Author: Klimek, Ludger, Buhl, Roland, Deitmer, Thomas, Plontke, Stefan, Wehrmann, Wolfgang, Merk, Hans, Ring, Johannes, Becker, Sven, Ärzteverband Deutscher Allergologen (AeDA) Becker Sven Klinik für Hals-, Nasen- und Ohrenheilkunde, Kopf- und Halschirurgie, Eberhard Karls Universität Tübingen, Tübingen, Germany Klimek Ludger Zentrum für Rhinologie und Allergologie Wiesbaden, Wiesbaden, Germany Merk Hans Abteilung Dermatologie & Allergologie, RWTH Aachen, Aachen, Germany Ring Johannes Haut- und Laserzentrum an der Oper, Munich, Germany Wehrmann Wolfgang Dermatologische Gemeinschaftspraxis Wehrmann, Münster, Germany, and Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC) Deitmer Thomas Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie, Bonn, Germany Plontke Stefan Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany
Subjects: Oto/Rhino/Laryngology, Intoxicative inhalant, Budesonide, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, General surgery, language.human_language, German, Otorhinolaryngology, language, medicine, Head and neck surgery, Position paper, ddc:610, business, Head and Neck Surgery, Allergology, Plastic Surgery, medicine.drug
Abstract: HNO : Hals-Nasen-Ohren-Heilkunde, Kopf- und Halschirurgie (2021). doi:10.1007/s00106-021-01070-9, Published by Springer, New York
Published: 2021

7. Recommendations for use of topical inhalant budesonide in COVID-19

Author: Klimek, Ludger, Buhl, Roland, Deitmer, Thomas, Plontke, Stefan, Wehrmann, Wolfgang, Merk, Hans, Ring, Johannes, and Becker, Sven
Subjects: Otolaryngology, SARS-CoV-2, COVID-19, Humans, Position Paper, Budesonide
Published: 2021

8. Stellungnahme zum Einsatz von topisch-inhalativem Budesonid bei COVID-19-Infektion

Author: Klimek, Ludger, Buhl, Roland, Deitmer, Thomas, Plontke, Stefan, Wehrmann, Wolfgang, Merk, Hans, Ring, Johannes, Becker, Sven, Ärzteverband Deutscher Allergologen (AeDA) Becker Sven Klinik für Hals-, Nasen- und Ohrenheilkunde, Kopf- und Halschirurgie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland Klimek Ludger Zentrum für Rhinologie und Allergologie Wiesbaden, Wiesbaden, Deutschland Merk Hans Abteilung Dermatologie & Allergologie, RWTH Aachen, Aachen, Deutschland Ring Johannes Haut- und Laserzentrum an der Oper, München, Deutschland Wehrmann Wolfgang Dermatologische Gemeinschaftspraxis Wehrmann, Münster, Deutschland, and Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC) Deitmer Thomas Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie, Bonn, Deutschland Plontke Stefan Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie, Martin-Luther-Universität Halle-Wittenberg, Halle, Deutschland
Subjects: medicine.medical_specialty, 2019-20 coronavirus outbreak, Otorhinolaryngology, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine, Head and neck surgery, business, Head and Neck Surgery, Allergology, Plastic Surgery, Dermatology
Published: 2021

9. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort

Author: von Siemens, Sarah Marietta, Perneczky, Robert, Waschki, Benjamin, Lutter, Johanna I, Welte, Tobias, Jörres, Rudolf A, Kahnert, Kathrin, group, COSYCONET study, Andreas, Stefan, Bals, Robert, Behr, Jürgen, Vogelmeier, Claus F, Bewig, Burkhard, Buhl, Roland, Ewert, Ralf, Stubbe, Beate, Gogol, Manfred, Grohé, Christian, Hauck, Rainer, Held, Matthias, Jany, Berthold, Henke, Markus, Herth, Felix, Höffken, Gerd, Katus, Hugo A, Kirsten, Anne-Marie, Watz, Henrik, Koczulla, Rembert, Kenn, Klaus, Kronsbein, Juliane, Kropf-Sanchen, Cornelia, Lange, Christoph, Kauffmann-Guerrero, Diego, Zabel, Peter, Pfeifer, Michael, Randerath, Winfried J, Seeger, Werner, Studnicka, Michael, Taube, Christian, Teschler, Helmut, Timmermann, Hartmut, Virchow, J Christian, Vogelmeier, Claus, Alter, Peter, Wagner, Ulrich, Wirtz, Hubert, Trudzinski, Franziska C, and Söhler, Sandra
Subjects: Male, medicine.medical_specialty, epidemiology [Cognitive Dysfunction], psychology [Pulmonary Disease, Chronic Obstructive], Medizin, Comorbidity, Cohort Studies, 03 medical and health sciences, FEV1/FVC ratio, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Cognition, epidemiology [Pulmonary Disease, Chronic Obstructive], Surveys and Questionnaires, medicine, Dementia, Humans, COPD, Cognitive Dysfunction, ddc:610, Cognitive skill, Path analysis (statistics), Aged, lcsh:RC705-779, business.industry, Research, physiology [Cognition], diagnosis [Pulmonary Disease, Chronic Obstructive], lcsh:Diseases of the respiratory system, Middle Aged, medicine.disease, Mental Status and Dementia Tests, humanities, Cross-Sectional Studies, Cognitive impairment, diagnosis [Cognitive Dysfunction], 030228 respiratory system, Cohort, Physical therapy, Female, psychology [Cognitive Dysfunction], business, 030217 neurology & neurosurgery, Cognitive load
Abstract: Alterations of cognitive functions have been described in COPD. Our study aimed to disentangle the relationship between the degree of cognitive function and COPD characteristics including quality of life (QoL).Data from 1969 COPD patients of the COSYCONET cohort (GOLD grades 1–4; 1216 male/ 753 female; mean (SD) age 64.9 ± 8.4 years) were analysed using regression and path analysis. The DemTect screening tool was used to measure cognitive function, and the St. George‘s respiratory questionnaire (SGRQ) to assess disease-specific QoL.DemTect scores were =60 years of age. For statistical reasons, we used the average of both algorithms independent of age in all subsequent analyses. The DemTect scores were associated with oxygen content, 6-min-walking distance (6-MWD), C-reactive protein (CRP), modified Medical Research Council dyspnoea scale (mMRC) and the SGRQ impact score. Conversely, the SGRQ impact score was independently associated with 6-MWD, FVC, mMRC and DemTect. These results were combined into a path analysis model to account for direct and indirect effects. The DemTect score had a small, but independent impact on QoL, irrespective of the inclusion of COPD-specific influencing factors or a diagnosis of cognitive impairment.We conclude that in patients with stable COPD lower oxygen content of blood as a measure of peripheral oxygen supply, lower exercise capacity in terms of 6-MWD, and higher CRP levels were associated with reduced cognitive capacity. Furthermore, a reduction in cognitive capacity was associated with reduced disease-specific quality of life. As a potential clinical implication of this work, we suggest to screen especially patients with low oxygen content and low 6-MWD for cognitive impairment.
Published: 2022
Full Text: View/download PDF

10. Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study

Author: Hechtner, Marlene, Eichler, Martin, Wehler, Beatrice, Buhl, Roland, Sebastian, Martin, Stratmann, Jan, Schmidberger, Heinz, Gohrbandt, Bernhard, Peuser, Jessica, Kortsik, Cornelius, Nestle, Ursula, Wiesemann, Sebastian, Wirtz, Hubert, Wehler, Thomas, Bals, Robert, Blettner, Maria, and Singer, Susanne
Subjects: Quality of life, Lung cancer, Survivor, Patient-reported outcome, Predictor
Published: 2022
Full Text: View/download PDF

11. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma

Author: Drick, Nora, Milger, Katrin, Seeliger, Benjamin, Fuge, Jan, Korn, Stephanie, Buhl, Roland, Schuhmann, Maren, Herth, Felix, Kendziora, Benjamin, Behr, Juergen, Kneidinger, Nikolaus, Bergmann, Karl-Christian, Taube, Christian, Welte, Tobias, and Suhling, Hendrik
Subjects: severe asthma, benralizumab, Medizin, mepolizumab, eosinophils, reslizumab, Original Research
Abstract: Background: Anti-IL-5 antibodies represent an established therapy for severe eosinophilic asthma (SEA), but some patients show inadequate response. The objective of this study was to assess the effects of a switch to anti-IL-5Rα therapy in patients with inadequate response to anti-IL-5 therapy. Methods: In this retrospective multi-centre, real-life study, we analysed all SEA patients switched from anti-IL-5 to anti-IL-5Rα therapy due to inadequate response or intolerability. Pulmonary function tests, blood gas analyses, asthma control tests (ACT) and oral corticos-teroid (OCS) usage were analysed and compared at three timepoints: baseline (BL, before anti-IL-5 therapy), timepoint 1 (T1, under anti-IL-5 therapy) and timepoint 2 (T2, under anti-IL-5Rα therapy). Results: Of 665 patients treated with anti-IL-5 antibodies, 70 were switched to anti-IL-5Rα and 60 were included in the analysis. Median treatment duration was 8 months [IQR 5; 15] for anti-IL-5 and 5 months [IQR 4; 6] for anti-IL-5Rα therapy. FEV₁ was 61% of predicted at BL [IQR 41; 74], 61% [IQR 43; 79] at T1 and 68% [IQR 49; 87] at T2 (pT₁₋T₂=0.011). ACT score was 10 [IQR 8; 13], 16 [IQR 10; 19] and 19 [IQR 14; 22], respectively (both p
Published: 2020

12. Nationale VersorgungsLeitlinie Asthma: Langfassung

Author: Schulz, Martin, Martin, Eric, Dalhoff, Klaus, Schäfer, Harald, Alsdorf, Elke, Köhler, Michael, Worth, Heinrich, Crilée, Carl-Peter, Weber, Michael, Hellmann, Andreas, Lommatzsch, Marek, Hamelmann, Eckard, Taube, Christian, Schneider, Antonius, Freitag, Michael, Nowak, Dennis, Kraus, Thomas, Ochmann, Uta, Kainer, Franz, Beule, Achim Georg, Hosemann, Werner, Klimek, Ludger, Buhl, Roland, Lepper, Philipp, Seiler, Frederik, Schuster, Antje, Kopp, Matthias, Schultz, Konrad, Virchow, Johann-Christian, Hering, Thomas, Dieter, Hans-Christian, Weber, Cora, Orth, Maritta, Hein, Holger, Kaufmann, Jan, Pfeiffer-Kascha, Dorothea, Reiter, Karl, Vogelberg, Christian, Spindler, Thomas, Gappa, Monika, Gerstlauer, Michael, Langhorst, Jost, and Klose, Petra
Published: 2022

13. Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET

Author: Trudzinski, F.C., Jörres, R.A., Alter, P., Kahnert, K., Waschki, B., Herr, C., Kellerer, C., Omlor, A., Vogelmeier, C.F., Fähndrich, S., Watz, H., Welte, T., Jany, B., Söhler, S., Biertz, F., Herth, F., Kauczor, H.-U., Bals, R., Andreas, Stefan, Behr, Jürgen, Bewig, Burkhard, Buhl, Roland, Ewert, Ralf, Stubbe, Beate, Ficker, Joachim H., Gogol, Manfred, Grohé, Christian, Hauck, Rainer, Held, Matthias, Henke, Markus, Höffken, Gerd, Katus, Hugo A., Kirsten, Anne-Marie, Koczulla, Rembert, Kenn, Klaus, Kronsbein, Juliane, Kropf-Sanchen, Lange, Christoph, Zabel, Peter, Pfeifer, Michael, Randerath, Winfried J., Seeger, Werner, Studnicka, Michael, Taube, Christian, Teschler, Helmut, Timmermann, Hartmut, Virchow, J. Christian, Wagner, and Wirtz, Hubert
Subjects: Adult, Male, medicine.medical_specialty, Exacerbation, Medizin, lcsh:Medicine, Severity of Illness Index, Gastroenterology, Article, Pulmonary Disease, Chronic Obstructive, 03 medical and health sciences, Medical research, 0302 clinical medicine, Internal medicine, medicine, Humans, 030212 general & internal medicine, Signs and symptoms, lcsh:Science, Survival rate, Aged, Oxygen saturation (medicine), Aged, 80 and over, Inflammation, COPD, Oxygenated Hemoglobin, Multidisciplinary, Proportional hazards model, business.industry, Hazard ratio, lcsh:R, Middle Aged, Prognosis, medicine.disease, Comorbidity, Survival Rate, Risk factors, 030228 respiratory system, Oxyhemoglobins, Female, lcsh:Q, Blood Gas Analysis, business, Biomarkers
Abstract: We studied whether in patients with stable COPD blood gases (BG), especially oxygenated hemoglobin (OxyHem) as a novel biomarker confer information on disease burden and prognosis and how this adds to the information provided by the comorbidity pattern and systemic inflammation. Data from 2137 patients (GOLD grades 1–4) of the baseline dataset of the COSYCONET COPD cohort were used. The associations with dyspnea, exacerbation history, BODE-Index (cut-off ≤2) and all-cause mortality over 3 years of follow-up were determined by logistic and Cox regression analyses, with sex, age, BMI and pack years as covariates. Predictive values were evaluated by ROC curves. Capillary blood gases included SaO2, PaO2, PaCO2, pH, BE and the concentration of OxyHem [haemoglobin (Hb) x fractional SaO2, g/dL] as a simple-to-measure correlate of oxygen content. Inflammatory markers were WBC, CRP, IL-6 and -8, TNF-alpha and fibrinogen, and comorbidities comprised a broad panel including cardiac and metabolic disorders. Among BG, OxyHem was associated with dyspnoea, exacerbation history, BODE-Index and mortality. Among inflammatory markers and comorbidities, only WBC and heart failure were consistently related to all outcomes. ROC analyses indicated that OxyHem provided information of a magnitude comparable to that of WBC, with optimal cut-off values of 12.5 g/dL and 8000/µL, respectively. Regarding mortality, OxyHem also carried independent, additional information, showing a hazard ratio of 2.77 (95% CI: 1.85–4.15, p 8000/µL was 2.33 (95% CI: 1.60–3.39, p 2. It thus appears well suited for clinical use with minimal equipment, especially for GPs.
Published: 2020

14. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemiea, b, c

Author: Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Kothari, Akash, Matucci, Andrea, Palomares, Oscar, Szépfalusi, Zsolt, Pohl, Wolfgang, Hötzenecker, Wolfram, Rosenkranz, Alexander, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Claus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Mülleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink Wagner, Antje, Horak, Fritz, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Mübecell, Matricardi, Paolo M., Spertini, François, Khaltaev, Nikolai, Michel, Jean-Pierre, Nicod, Larent, Schmid-Grendelmeier, Peter, Idzko, Marco, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, Francois, Schwarze, Jürgen, O´Mahony, Liam, Knol, Edward, del Giacco, Stefano, Chivato, Tomás, Bousquet, Jean, Zuberbier, Torsten, Akdis, Cezmi, and Jutel, Marek
Subjects: Titel, SARS-CoV-2, Medizin, Immunology and Allergy, Omalizumab, Benralizumab, Dupilumab, Reslizumab, Covid-19, Telemedizin, Mepolizumab
Published: 2020

15. Corrigendum to 'The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control'

Author: Korn, Stephanie, Milger, Katrin, Skowasch, Dirk, Timmermann, Hartmut, Taube, Christian, Idzko, Marco, Voß, Hans Werner, Holtdirk, Annette, Hamelmann, Eckard, and Buhl, Roland
Subjects: Medizin
Abstract: The authors regret that Sanofi, one of the funders of the German Asthma Net, was omitted from the acknowledgements and funding section of the manuscript. The full disclosure should read: The GAN Severe Asthma Registry is supported by the German Asthma Net e.V., a German nonprofit society, and is funded by the German Ministry for Education and Research in the CHAMP consortium (BMBF, 01GL1742D); the GAN is also being funded by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi, and Teva. The authors would like to apologise for any inconvenience caused.
Published: 2022

16. Real-world treatment of patients with incident chronic obstructive pulmonary disease, stratified by airflow limitation at time of diagnosis

Author: Vogelmeier, Claus, Picker, Nils, Hechtner, Marlene, Kondla, Anke, Hofmann, Patrick, Maywald, Ulf, Wilke, Thomas, and Buhl, Roland
Subjects: ddc: 610, Medicine and health, respiratory tract diseases
Abstract: Background: Long-acting bronchodilators (LABA/LAMA) are the cornerstone of pharmacotherapy in COPD, and current guidelines recommend their use as first-line therapy in symptomatic COPD patients. Given the course of COPD, patients are likely to switch drugs in daily practice. Research question [for full text, please go to the a.m. URL]
Published: 2021
Full Text: View/download PDF

17. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort

Author: Heaney, Liam G., Perez de Llano, Luis, Al-Ahmad, Mona, Backer, Vibeke, Busby, John, Canonica, Giorgio Walter, Christoff, George C., Cosio, Borja G., FitzGerald, J. Mark, Heffler, Enrico, Iwanaga, Takashi, Jackson, David J., Menzies-Gow, Andrew N., Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Pfeffer, Paul E., Popov, Todor A., Porsbjerg, Celeste M., Rhee, Chin Kook, Sadatsafavi, Mohsen, Tohda, Yuji, Wang, Eileen, Wechsler, Michael E., Alacqua, Marianna, Altraja, Alan, Bjermer, Leif, Björnsdóttir, Unnur S., Bourdin, Arnaud, Brusselle, Guy G., Buhl, Roland, Costello, Richard W., Hew, Mark, Koh, Mariko Siyue, Lehmann, Sverre, Lehtimäki, Lauri, Peters, Matthew, Taillé, Camille, Taube, Christian, Tran, Trung N., Zangrilli, James, Bulathsinhala, Lakmini, Carter, Victoria A., Chaudhry, Isha, Eleangovan, Neva, Hosseini, Naeimeh, Kerkhof, Marjan, Murray, Ruth B., Price, Chris A., Price, David B., Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Epidemiology, Tampere University, Department of Respiratory medicine, Dermatology and Allergology, and Clinical Medicine
Subjects: PROTOCOL, Adult, Male, Asia, [SDV]Life Sciences [q-bio], Medizin, 3121 Internal medicine, Global Health, Severity of Illness Index, VALIDATION, International Severe Asthma Registry, MECHANISMS, Cohort Studies, Leukocyte Count, Middle East, Adrenal Cortex Hormones, Eosinophilia, Medicine and Health Sciences, Prevalence, Humans, Anti-Asthmatic Agents, Registries, Age of Onset, PREDICTORS, ComputingMilieux_MISCELLANEOUS, RECEPTOR, BENRALIZUMAB, Middle Aged, Asthma, Patient Care Management, Respiratory Function Tests, Eosinophils, Europe, Biological Variation, Population, North America, Female, FENO
Abstract: Background: Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are not well characterized in global, real-life severe asthma cohorts. Research Question: What is the prevalence of eosinophilic and noneosinophilic phenotypes in the population with severe asthma, and can these phenotypes be differentiated by clinical and biomarker variables? Study Design and Methods: This was an historical registry study. Adult patients with severe asthma and available blood eosinophil count (BEC) from 11 countries enrolled in the International Severe Asthma Registry (January 1, 2015-September 30, 2019) were categorized according to likelihood of eosinophilic phenotype using a predefined gradient eosinophilic algorithm based on highest BEC, long-term oral corticosteroid use, elevated fractional exhaled nitric oxide, nasal polyps, and adult-onset asthma. Demographic and clinical characteristics were defined at baseline (ie, 1 year before or closest to date of BEC). Results: One thousand seven hundred sixteen patients with prospective data were included; 83.8% were identified as most likely (grade 3), 8.3% were identified as likely (grade 2), and 6.3% identified as least likely (grade 1) to have an eosinophilic phenotype, and 1.6% of patients showed a noneosinophilic phenotype (grade 0). Eosinophilic phenotype patients (ie, grades 2 or 3) showed later asthma onset (29.1 years vs 6.7 years; P < .001) and worse lung function (postbronchodilator % predicted FEV1, 76.1% vs 89.3%; P = .027) than those with a noneosinophilic phenotype. Patients with noneosinophilic phenotypes were more likely to be women (81.5% vs 62.9%; P = .047), to have eczema (20.8% vs 8.5%; P = .003), and to use anti-IgE (32.1% vs 13.4%; P = .004) and leukotriene receptor antagonists (50.0% vs 28.0%; P = .011) add-on therapy. Interpretation: According to this multicomponent, consensus-driven, and evidence-based eosinophil gradient algorithm (using variables readily accessible in real life), the severe asthma eosinophilic phenotype was more prevalent than previously identified and was phenotypically distinct. This pragmatic gradient algorithm uses variables readily accessible in primary and specialist care, addressing inherent issues of phenotype heterogeneity and phenotype instability. Identification of treatable traits across phenotypes should improve therapeutic precision. publishedVersion
Published: 2021

18. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting

Author: Steinmetz, Karl-Otto, Abenhardt, Birgit, Pabst, Stefan, Hänsel, Michaela, Kondla, Anke, Bayer, Valentina, and Buhl, Roland
Subjects: Male, Time Factors, physical activity, Muscarinic Antagonists, chronic obstructive pulmonary disease, Pulmonary Disease, Chronic Obstructive, tiotropium, Administration, Inhalation, Humans, Tiotropium Bromide, Adrenergic beta-2 Receptor Agonists, Lung, Original Research, Aged, Exercise Tolerance, olodaterol, noninterventional study, Nebulizers and Vaporizers, Recovery of Function, Middle Aged, Benzoxazines, Bronchodilator Agents, Drug Combinations, Treatment Outcome, Patient Satisfaction, Female
Abstract: Background Patients with chronic obstructive pulmonary disease (COPD) show signs of reduced physical activity from the early stages of the disease, impacting morbidity and mortality. Data suggest treatment with tiotropium, a long-acting muscarinic antagonist, and olodaterol, a long-acting ß2-agonist (LABA), as monotherapies and in combination, increases exercise capacity. This study assessed the effects of fixed-dose tiotropium/olodaterol (delivered via Respimat®) on physical function in Global Initiative for Chronic Obstructive Lung Disease A–D patients requiring long-acting dual bronchodilation treatment in a real-world setting. Methods This open-label, single arm, noninterventional study measured changes in physical function in COPD patients treated with tiotropium/olodaterol 5/5 μg for approximately 6 weeks (between Visit 1 [baseline] and Visit 2). Primary end point was therapeutic success, defined as a minimum 10-point increase in Physical Functioning Questionnaire (PF-10) score. Secondary end points included change in PF-10 from Visit 1 to Visit 2, the patient’s general condition (measured by Physician’s Global Evaluation score) at Visit 1 and Visit 2, and patient satisfaction with treatment delivered via the Respimat® device (assessed by Patient Satisfaction Questionnaire) at study end. Results Therapeutic success was observed in 51.5% of 1578 patients (95% confidence interval [CI] 49.0, 54.0) after approximately 6 weeks of treatment with tiotropium/olodaterol. Mean change in PF-10 score between Visit 1 and Visit 2 was 11.6 points (95% CI 10.7, 12.6). Patient general condition improved as indicated by a general improvement in scores between visits. Most patients were very satisfied or satisfied with tiotropium/olodaterol treatment (82.5%), inhalation (87.5%), and handling of Respimat® (85.2%). One percent of patients reported an investigator-defined drug-related adverse events (AE). Conclusion Tiotropium/olodaterol treatment improved physical functioning in COPD patients. An associated increase in patient general condition was observed. Most patients were very satisfied or satisfied with tiotropium/olodaterol treatment, inhaling, and handling of the Respimat® device. No unexpected drug-related AE occurred.
Published: 2019

19. Eosinophilic and Noneosinophilic Asthma An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort

Author: Heaney, Liam G. de Llano, Luis Perez Al-Ahmad, Mona Backer, Vibeke Busby, John Canonica, Giorgio Walter Christoff, George C. Cosio, Borja G. FitzGerald, J. Mark Heffler, Enrico Iwanaga, Takashi Jackson, David J. Menzies-Gow, Andrew N. Papadopoulos, Nikolaos G. Papaioannou, I, Andriana and Pfeffer, Paul E. Popov, Todor A. Porsbjerg, Celeste M. Rhee, Chin Kook Sadatsafavi, Mohsen Tohda, Yuji Wang, Eileen and Wechsler, Michael E. Alacqua, Marianna Altraja, Alan and Bjermer, Leif Bjornsdottir, Unnur S. Bourdin, Arnaud and Brusselle, Guy G. Buhl, Roland Costello, Richard W. Hew, Mark Koh, Mariko Siyue Lehmann, Sverre Lehtimaki, Lauri and Peters, Matthew Taille, Camille Taube, Christian Tran, Trung N. Zangrilli, James Bulathsinhala, Lakmini Carter, Victoria A. Chaudhry, Isha Eleangovan, Neva Hosseini, Naeimeh and Kerkhof, Marjan Murray, Ruth B. Price, Chris A. Price, David B.
Abstract: BACKGROUND: Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are not well characterized in global, real-life severe asthma cohorts. RESEARCH QUESTION: What is the prevalence of eosinophilic and noneosinophilic phenotypes in the population with severe asthma, and can these phenotypes be differentiated by clinical and biomarker variables? STUDY DESIGN AND METHODS: This was an historical registry study. Adult patients with severe asthma and available blood eosinophil count (BEC) from 11 countries enrolled in the International Severe Asthma Registry (January 1, 2015-September 30, 2019) were categorized according to likelihood of eosinophilic phenotype using a predefined gradient eosinophilic algorithm based on highest BEC, long-term oral corticosteroid use, elevated fractional exhaled nitric oxide, nasal polyps, and adult-onset asthma. Demographic and clinical characteristics were defined at baseline (ie, 1 year before or closest to date of BEC). RESULTS: One thousand seven hundred sixteen patients with prospective data were included; 83.8% were identified as most likely (grade 3), 8.3% were identified as likely (grade 2), and 6.3% identified as least likely (grade 1) to have an eosinophilic phenotype, and 1.6% of patients showed a noneosinophilic phenotype (grade 0). Eosinophilic phenotype patients (ie, grades 2 or 3) showed later asthma onset (29.1 years vs 6.7 years; P
Published: 2021

20. Returning to work in lung cancer survivors : a multi-center cross-sectional study in Germany

Author: Rashid, Humayra, Eichler, Martin, Hechtner, Marlene, Gianicolo, Emilio, Wehler, Beatrice, Buhl, Roland, Schmidberger, Heinz, Stratmann, Jan A., Gohrbandt, Bernhard, Kortsik, Cornelius, Nestle, Ursula, Wirtz, Hubert, Blettner, Maria, and Singer, Susanne
Subjects: 610 Medical sciences, 610 Medizin
Published: 2021
Full Text: View/download PDF

21. Digital transformation of health and care in airway diseases from research to practice

Author: Bousquet, Jean, Anto, Josep M., Bachert, Claus, Haahtela, Tari, Zuberbier, Torsten, Czarlewski, Wienczyslawa, Bedbrook, Anna, Bosnic-Anticevich, Sinthia, Walter Canonica, G., Cardona, Victoria, Costa, Elisio, Cruz, Alvaro A., Erhola, Marina, Fokkens, Wytske J., Fonseca, Joao A., Illario, Maddalena, Ivancevich, Juan Carlos, Jutel, Marek, Klimek, Ludger, Kuna, Piotr, Kvedariene, Violeta, Le, L. T.T., Larenas-Linnemann, Désirée E., Laune, Daniel, Lourenço, Olga M., Melén, Erik, Mullol, Joaquim, Niedoszytko, Marek, Odemyr, Mikaëla, Okamoto, Yoshitaka, Papadopoulos, Nikos G., Patella, Vincenzo, Pfaar, Oliver, Pham-Thi, Nhân, Rolland, Christine, Samolinski, Boleslaw, Sheikh, Aziz, Sofiev, Mikhail, Suppli Ulrik, Charlotte, Todo-Bom, Ana, Tomazic, Peter Valentin, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Valiulis, Arunas, Valovirta, Erkka, Ventura, Maria Teresa, Walker, Samantha, Williams, Sian, Yorgancioglu, Arzu, Agache, Ioana, Akdis, Cezmi A., Almeida, Rute, Ansotegui, Ignacio J., Annesi-Maesano, Isabella, Arnavielhe, Sylvie, Basagaña, Xavier, D. Bateman, Eric, Bédard, Annabelle, Bedolla-Barajas, Martin, Becker, Sven, Bennoor, Kazi S., Benveniste, Samuel, Bergmann, Karl C., Bewick, Michael, Bialek, Slawomir, E. Billo, Nils, Bindslev-Jensen, Carsten, Bjermer, Leif, Blain, Hubert, Bonini, Matteo, Bonniaud, Philippe, Bosse, Isabelle, Bouchard, Jacques, Boulet, Louis Philippe, Bourret, Rodolphe, Boussery, Koen, Braido, Fluvio, Briedis, Vitalis, Briggs, Andrew, Brightling, Christopher E., Brozek, Jan, Brusselle, Guy, Brussino, Luisa, Buhl, Roland, Buonaiuto, Roland, Calderon, Moises A., Camargos, Paulo, Camuzat, Thierry, Caraballo, Luis, Carriazo, Ana Maria, Carr, Warner, Cartier, Christine, Casale, Thomas, Cecchi, Lorenzo, Cepeda Sarabia, Alfonso M., H. Chavannes, Niels, Chkhartishvili, Ekaterine, Chu, Derek K., Cingi, Cemal, Correia de Sousa, Jaime, Costa, David J., Courbis, Anne Lise, Custovic, Adnan, Cvetkosvki, Biljana, D'Amato, Gennaro, da Silva, Jane, Dantas, Carina, Dokic, Dejan, Dauvilliers, Yves, De Feo, Giulia, De Vries, Govert, Devillier, Philippe, Di Capua, Stefania, Dray, Gerard, Dubakiene, Ruta, Durham, Stephen R., Dykewicz, Marc, Ebisawa, Motohiro, Gaga, Mina, El-Gamal, Yehia, Heffler, Enrico, Emuzyte, Regina, Farrell, John, Fauquert, Jean Luc, Fiocchi, Alessandro, Fink-Wagner, Antje, Fontaine, Jean François, Fuentes Perez, José M., Gemicioğlu, Bilun, Gamkrelidze, Amiran, Garcia-Aymerich, Judith, Gevaert, Philippe, Gomez, René Maximiliano, González Diaz, Sandra, Gotua, Maia, Guldemond, Nick A., Guzmán, Maria Antonieta, Hajjam, Jawad, Huerta Villalobos, Yunuen R., Humbert, Marc, Iaccarino, Guido, Ierodiakonou, Despo, Iinuma, Tomohisa, Jassem, Ewa, Joos, Guy, Jung, Ki Suck, Kaidashev, Igor, Kalayci, Omer, Kardas, Przemyslaw, Keil, Thomas, Khaitov, Musa, Khaltaev, Nikolai, Kleine-Tebbe, Jorg, Kouznetsov, Rostislav, Kowalski, Marek L., Kritikos, Vicky, Kull, Inger, La Grutta, Stefania, Leonardini, Lisa, Ljungberg, Henrik, Lieberman, Philip, Lipworth, Brian, Lodrup Carlsen, Karin C., Lopes-Pereira, Catarina, Loureiro, Claudia C., Louis, Renaud, Mair, Alpana, Mahboub, Bassam, Makris, Michaël, Malva, Joao, Manning, Patrick, Marshall, Gailen D., Masjedi, Mohamed R., Maspero, Jorge F., Carreiro-Martins, Pedro, Makela, Mika, Mathieu-Dupas, Eve, Maurer, Marcus, De Manuel Keenoy, Esteban, Melo-Gomes, Elisabete, Meltzer, Eli O., Menditto, Enrica, Mercier, Jacques, Micheli, Yann, Miculinic, Neven, Mihaltan, Florin, Milenkovic, Branislava, Mitsias, Dimitirios I., Moda, Giuliana, Mogica-Martinez, Maria Dolores, Mohammad, Yousser, Montefort, Steve, Monti, Ricardo, Morais-Almeida, Mario, Mösges, Ralph, Münter, Lars, Muraro, Antonella, Murray, Ruth, Naclerio, Robert, Napoli, Luigi, Namazova-Baranova, Leyla, Neffen, Hugo, Nekam, Kristoff, Neou, Angelo, Nordlund, Björn, Novellino, Ettore, Nyembue, Dieudonné, O'Hehir, Robyn, Ohta, Ken, Okubo, Kimi, Onorato, Gabrielle L., Orlando, Valentina, Ouedraogo, Solange, Palamarchuk, Julia, Pali-Schöll, Isabella, Panzner, Peter, Park, Hae Sim, Passalacqua, Gianni, Pépin, Jean Louis, Paulino, Ema, Pawankar, Ruby, Phillips, Jim, Picard, Robert, Pinnock, Hilary, Plavec, Davor, Popov, Todor A., Portejoie, Fabienne, Price, David, Prokopakis, Emmanuel P., Psarros, Fotis, Pugin, Benoit, Puggioni, Francesca, Quinones-Delgado, Pablo, Raciborski, Filip, Rajabian-Söderlund, Rojin, Regateiro, Frederico S., Reitsma, Sietze, Rivero-Yeverino, Daniela, Roberts, Graham, Roche, Nicolas, Rodriguez-Zagal, Erendira, Roller-Wirnsberger, Regina E., Rosario, Nelson, Romano, Antonino, Rottem, Menachem, Ryan, Dermot, Salimäki, Johanna, Sanchez-Borges, Mario M., Sastre, Joaquin, Scadding, Glenis K., Scheire, Sophie, Schmid-Grendelmeier, Peter, Schünemann, Holger J., Sarquis Serpa, Faradiba, Shamji, Mohamed, Sisul, Juan Carlos, Solé, Dirceu, Somekh, David, Sooronbaev, Talant, Sova, Milan, Spertini, François, Spranger, Otto, Stellato, Cristiana, Stelmach, Rafael, Thibaudon, Michel, To, Teresa, Toumi, Mondher, Usmani, Omar, Valero, Antonio A., Valenta, Rudolph, Valentin-Rostan, Marylin, Pereira, Marilyn Urrutia, van der Kleij, Rianne, Van Eerd, Michiel, Vandenplas, Olivier, Vasankari, Tuula, Vaz Carneiro, Antonio, Vezzani, Giorgio, Viart, Frédéric, Viegi, Giovanni, Wallace, Dana, Wagenmann, Martin, Wang, De Yun, Waserman, Susan, Wickman, Magnus, Williams, Dennis M., Wong, Gary, Wroczynski, Piotr, Yiallouros, Panayiotis K., Yusuf, Osman M., Zar, Heather J., Zeng, Stéphane, Zernotti, Mario E., Zhang, Luo, Shan Zhong, Nan, Zidarn, Mihaela, and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Subjects: ARIA, rhinitis, CARAT, MASK, Immunology, Immunology and Allergy, asthma, digital transformation of health and care
Abstract: Funding: MA reports personal fees from POCI-01-0145-FEDER-029130 mINSPIRERS—mHealth to measure and improve adherence to medication in chronic obstructive respiratory diseases—generalization and evaluation of gamification, peer support and advanced image processing technologies from ERDF (European Regional Development Fund) funded by the COMPETE2020 and by National Funds through FCT (Fundação para a Ciência e a Tecnologia)… Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed. publishersversion published
Published: 2021

22. ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice

Author: Bousquet, Jean Anto, Josep M. Bachert, Claus Haahtela, Tari and Zuberbier, Torsten Czarlewski, Wienczyslawa Bedbrook, Anna and Bosnic-Anticevich, Sinthia Walter Canonica, G. Cardona, Victoria Costa, Elisio Cruz, Alvaro A. Erhola, Marina and Fokkens, Wytske J. Fonseca, Joao A. Illario, Maddalena and Ivancevich, Juan-Carlos Jutel, Marek Klimek, Ludger Kuna, Piotr Kvedariene, Violeta Le, L. T. T. Larenas-Linnemann, Desiree E. Laune, Daniel Lourenco, Olga M. Melen, Erik and Mullol, Joaquim Niedoszytko, Marek Odemyr, Mikaela Okamoto, Yoshitaka Papadopoulos, Nikos G. Patella, Vincenzo Pfaar, Oliver Pham-Thi, Nhan Rolland, Christine Samolinski, Boleslaw Sheikh, Aziz Sofiev, Mikhail Suppli Ulrik, Charlotte Todo-Bom, Ana Tomazic, Peter-Valentin and Toppila-Salmi, Sanna Tsiligianni, Ioanna Valiulis, Arunas and Valovirta, Erkka Ventura, Maria-Teresa Walker, Samantha and Williams, Sian Yorgancioglu, Arzu Agache, Ioana Akdis, Cezmi A. Almeida, Rute Ansotegui, Ignacio J. Annesi-Maesano, Isabella Arnavielhe, Sylvie Basagana, Xavier D. Bateman, Eric Bedard, Annabelle Bedolla-Barajas, Martin Becker, Sven and Bennoor, Kazi S. Benveniste, Samuel Bergmann, Karl C. and Bewick, Michael Bialek, Slawomir E. Billo, Nils and Bindslev-Jensen, Carsten Bjermer, Leif Blain, Hubert Bonini, Matteo Bonniaud, Philippe Bosse, Isabelle Bouchard, Jacques and Boulet, Louis-Philippe Bourret, Rodolphe Boussery, Koen and Braido, Fluvio Briedis, Vitalis Briggs, Andrew Brightling, Christopher E. Brozek, Jan Brusselle, Guy Brussino, Luisa and Buhl, Roland Buonaiuto, Roland Calderon, Moises A. and Camargos, Paulo Camuzat, Thierry Caraballo, Luis Carriazo, Ana-Maria Carr, Warner Cartier, Christine Casale, Thomas and Cecchi, Lorenzo Cepeda Sarabia, Alfonso M. H. Chavannes, Niels and Chkhartishvili, Ekaterine Chu, Derek K. Cingi, Cemal and Correia de Sousa, Jaime Costa, David J. Courbis, Anne-Lise and Custovic, Adnan Cvetkosvki, Biljana D'Amato, Gennaro da Silva, Jane Dantas, Carina Dokic, Dejan Dauvilliers, Yves and De Feo, Giulia De Vries, Govert Devillier, Philippe Di Capua, Stefania Dray, Gerard Dubakiene, Ruta Durham, Stephen R. Dykewicz, Marc Ebisawa, Motohiro Gaga, Mina El-Gamal, Yehia Heffler, Enrico Emuzyte, Regina Farrell, John and Fauquert, Jean-Luc Fiocchi, Alessandro Fink-Wagner, Antje and Fontaine, Jean-Francois Fuentes Perez, Jose M. Gemicioglu, Bilun and Gamkrelidze, Amiran Garcia-Aymerich, Judith Gevaert, Philippe Gomez, Rene Maximiliano Gonzalez Diaz, Sandra and Gotua, Maia Guldemond, Nick A. Guzman, Maria-Antonieta and Hajjam, Jawad Huerta Villalobos, Yunuen R. Humbert, Marc and Iaccarino, Guido Ierodiakonou, Despo Iinuma, Tomohisa and Jassem, Ewa Joos, Guy Jung, Ki-Suck Kaidashev, Igor and Kalayci, Omer Kardas, Przemyslaw Keil, Thomas Khaitov, Musa and Khaltaev, Nikolai Kleine-Tebbe, Jorg Kouznetsov, Rostislav and Kowalski, Marek L. Kritikos, Vicky Kull, Inger La Grutta, Stefania Leonardini, Lisa Ljungberg, Henrik and Lieberman, Philip Lipworth, Brian Lodrup Carlsen, Karin C. and Lopes-Pereira, Catarina Loureiro, Claudia C. Louis, Renaud and Mair, Alpana Mahboub, Bassam Makris, Michael Malva, Joao and Manning, Patrick Marshall, Gailen D. Masjedi, Mohamed R. and Maspero, Jorge F. Carreiro-Martins, Pedro Makela, Mika and Mathieu-Dupas, Eve Maurer, Marcus De Manuel Keenoy, Esteban and Melo-Gomes, Elisabete Meltzer, Eli O. Menditto, Enrica and Mercier, Jacques Micheli, Yann Miculinic, Neven Mihaltan, Florin Milenkovic, Branislava Mitsias, Dimitirios I. Moda, Giuliana Mogica-Martinez, Maria-Dolores Mohammad, Yousser and Montefort, Steve Monti, Ricardo Morais-Almeida, Mario and Mosges, Ralph Munter, Lars Muraro, Antonella Murray, Ruth and Naclerio, Robert Napoli, Luigi Namazova-Baranova, Leyla and Neffen, Hugo Nekam, Kristoff Neou, Angelo Nordlund, Bjorn and Novellino, Ettore Nyembue, Dieudonne O'Hehir, Robyn and Ohta, Ken Okubo, Kimi Onorato, Gabrielle L. Orlando, Valentina Ouedraogo, Solange Palamarchuk, Julia Pali-Scholl, Isabella Panzner, Peter Park, Hae-Sim Passalacqua, Gianni and Pepin, Jean-Louis Paulino, Ema Pawankar, Ruby Phillips, Jim Picard, Robert Pinnock, Hilary Plavec, Davor Popov, Todor A. Portejoie, Fabienne Price, David Prokopakis, Emmanuel P. Psarros, Fotis Pugin, Benoit Puggioni, Francesca and Quinones-Delgado, Pablo Raciborski, Filip and Rajabian-Soderlund, Rojin Regateiro, Frederico S. Reitsma, Sietze Rivero-Yeverino, Daniela Roberts, Graham Roche, Nicolas Rodriguez-Zagal, Erendira Rolland, Christine and Roller-Wirnsberger, Regina E. Rosario, Nelson Romano, Antonino and Rottem, Menachem Ryan, Dermot Salimaki, Johanna and Sanchez-Borges, Mario M. Sastre, Joaquin Scadding, Glenis K. and Scheire, Sophie Schmid-Grendelmeier, Peter Schunemann, Holger J. and Sarquis Serpa, Faradiba Shamji, Mohamed Sisul, Juan-Carlos and Sofiev, Mikhail Sole, Dirceu Somekh, David Sooronbaev, Talant Sova, Milan Spertini Spranger, Otto Stellato, Cristiana Stelmach, Rafael Thibaudon, Michel To, Teresa and Toumi, Mondher Usmani, Omar Valero, Antonio A. Valenta, Rudolph Valentin-Rostan, Marylin Pereira, Marilyn Urrutia and van der Kleij, Rianne Van Eerd, Michiel Vandenplas, Olivier and Vasankari, Tuula Vaz Carneiro, Antonio Vezzani, Giorgio and Viart, Frederic Viegi, Giovanni Wallace, Dana Wagenmann, Martin Wang, De Yun Waserman, Susan Wickman, Magnus and Williams, Dennis M. Wong, Gary Wroczynski, Piotr Yiallouros, Panayiotis K. Yusuf, Osman M. Zar, Heather J. Zeng, Stephane and Zernotti, Mario E. Zhang, Luo Shan Zhong, Nan Zidarn, Mihaela
Abstract: Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed.
Published: 2021

23. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma

Author: Drick,Nora, Milger,Katrin, Seeliger,Benjamin, Fuge,Jan, Korn,Stephanie, Buhl,Roland, Schuhmann,Maren, Herth,Felix, Kendziora,Benjamin, Behr,Juergen, Kneidinger,Nikolaus, Bergmann,Karl-Christian, Taube,Christian, Welte,Tobias, and Suhling,Hendrik
Subjects: Journal of Asthma and Allergy
Abstract: Nora Drick,1,* Katrin Milger,2,* Benjamin Seeliger,1 Jan Fuge,1 Stephanie Korn,3 Roland Buhl,3 Maren Schuhmann,4 Felix Herth,4 Benjamin Kendziora,5 Juergen Behr,2 Nikolaus Kneidinger,2 Karl-Christian Bergmann,5 Christian Taube,6 Tobias Welte,1 Hendrik Suhling1 1Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; 2Department of Internal Medicine V, Ludwig-Maximilians University of Munich (LMU), Munich, Germany; 3Pulmonary Department, Mainz University Hospital, Mainz, Germany; 4Department of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany; 5Allergy-Centre-Charité, Charité – Universitätsmedizin Berlin, Berlin, Germany; 6Department of Pulmonary Medicine, University Hospital Essen – Ruhrlandklinik, Essen, Germany*These authors contributed equally to this workCorrespondence: Hendrik Suhling Email suhling.hendrik@mh-hannover.deBackground: Anti-IL-5 antibodies represent an established therapy for severe eosinophilic asthma (SEA), but some patients show inadequate response. The objective of this study was to assess the effects of a switch to anti-IL-5Rα therapy in patients with inadequate response to anti-IL-5 therapy.Methods: In this retrospective multi-centre, real-life study, we analysed all SEA patients switched from anti-IL-5 to anti-IL-5Rα therapy due to inadequate response or intolerability. Pulmonary function tests, blood gas analyses, asthma control tests (ACT) and oral corticosteroid (OCS) usage were analysed and compared at three timepoints: baseline (BL, before anti-IL-5 therapy), timepoint 1 (T1, under anti-IL-5 therapy) and timepoint 2 (T2, under anti-IL-5Rα therapy).Results: Of 665 patients treated with anti-IL-5 antibodies, 70 were switched to anti-IL-5Rα and 60 were included in the analysis. Median treatment duration was 8 months [IQR 5; 15] for anti-IL-5 and 5 months [IQR 4; 6] for anti-IL-5Rα therapy. FEV1 was 61% of predicted at BL [IQR 41; 74], 61% [IQR 43; 79] at T1 and 68% [IQR 49; 87] at T2 (pT1-T2=0.011). ACT score was 10 [IQR 8; 13], 16 [IQR 10; 19] and 19 [IQR 14; 22], respectively (both p< 0.001). The number of patients requiring OCS was reduced from 41 (BL) to 32 (T1) and 19 (T2) (both p< 0.001). Ten patients discontinued anti-IL-5Rα therapy due to insufficient efficacy (n=7) and adverse events (n=3).Conclusion: Switching from anti-IL-5 to anti-IL-5Rα therapy in patients with inadequate response was associated with significantly improved FEV1, asthma control and OCS reduction.Keywords: benralizumab, eosinophils, mepolizumab, reslizumab, severe asthma
Published: 2020

24. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemie

Author: Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Kothari, Akash, Matucci, Andrea, Palomares, Oscar, Szépfalusi, Zsolt, Pohl, Wolfgang, Hötzenecker, Wolfram, Rosenkranz, Alexander, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, et al, University of Zurich, and Klimek, Ludger
Subjects: 10183 Swiss Institute of Allergy and Asthma Research, 2723 Immunology and Allergy, 10177 Dermatology Clinic, Immunology and Allergy, 610 Medicine & health
Published: 2020

25. Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET

Author: Kirsten Anne-Marie, Anne Wirz, Erich Traugott, Ficker Joachim H, Bertram J. Jobst, Vivien Janke, Stubbe Beate, Johanna I. Lutter, Barbara Ziss, Franziska C. Trudzinski, Patricia Berger, Henrik Watz, Gogol Manfred, Thomas Bahmer, Beate Polte, Kronsbein Juliane, Campus Kiel, Lange Christoph, Martina Seibert, Rudolf A. Jörres, Pfeifer Michael, Timmermann Hartmut, Grohé Christian, Tobias Welte, Studnicka Michael, Petra Hundack-Winter, Jana Graf, Jürgen Behr, Diana Schottel, Buhl Roland, Virchow J. Christian, Bewig Burkhard, Ruhrlandklinik gGmbH. Essen, Wirtz Hubert, Rosalie Untsch, Birte Struck, Peter Alter, Kathrin Kahnert, Gudrun Hübner, Vogelmeier Claus, Sabine Michalewski, Kropf-Sanchen Cornelia, Kenn Klaus, Pontus Mertsch, Sonja Rohweder, Hauck Rainer, Andreas Stefan, Ilona Kietzmann, Zabel Peter, Michaela Schrade-Illmann, Höffken Gerd, Julia Tobias, Frank Biertz, Seeger Werner, Manuel Klöser, Kahnert Kathrin, Teschler Helmut, Anita Reichel, Gina Spangel, Ulrike Rieber, Randerath Winfried J, Julia Teng, Tanja Lucke, Herth Felix, Jeanette Pieper, Lenka Krabbe, Taube Christian, Jürgen Biederer, Wagner Ulrich, Doris Lehnert, Claus Vogelmeier, Katrin Schwedler, Henke Markus, Jany Berthold, Katus Hugo A, Bals Robert, Zaklina Hinz, Cornelia Böckmann, Ellen Burmann, Margret Gleiniger, Behr Jürgen, Britta Markworth, Ewert Ralf, Gertraud Weiß, Katrin Wons, Barbara Arikan, Watz Henrik, Beate Schaufler, Lena Sterk, Robert Bals, Hans-Ulrich Kauczor, Koczulla Rembert, Held Matthias, and Welte Tobias
Subjects: Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Copd patients, Medizin, Comorbidity, Severity of Illness Index, Pulmonary Disease, Chronic Obstructive, Medicine, Humans, In patient, Lung, Aged, Aged, 80 and over, COPD, Bronchiectasis, business.industry, Phlegm, Middle Aged, medicine.disease, Radiological weapon, Clinical diagnosis, Cohort, Female, Radiography, Thoracic, Radiology, medicine.symptom, business, Tomography, X-Ray Computed
Abstract: Bronchiectasis (BE) might be frequently present in COPD but masked by COPD symptoms. We studied the relationship of clinical signs of bronchiectasis to the presence and extent of its radiological signs in patients of different COPD severity. Visit 4 data (GOLD grades 1-4) of the COSYCONET cohort was used. Chest CT scans were evaluated for bronchiectasis in 6 lobes using a 3-point scale (0: absence, 1: ≤50%, 2: >50% BE-involvement for each lobe). 1176 patients were included (61%male, age 67.3y), among them 38 (3.2%) with reported physicians' diagnosis of bronchiectasis and 76 (6.5%) with alpha1-antitrypsin deficiency (AA1D). CT scans were obtained in 429 patients. Within this group, any signs of bronchiectasis were found in 46.6% of patients, whereby ≤50% BE occurred in 18.6% in ≤2 lobes, in 10.0% in 3-4 lobes, in 15.9% in 5-6 lobes; >50% bronchiectasis in at least 1 lobe was observed in 2.1%. Scores ≥4 correlated with an elevated ratio FRC/RV. The clinical diagnosis of bronchiectasis correlated with phlegm and cough and with radiological scores of at least 3, optimally ≥5. In COPD patients, clinical diagnosis and radiological signs of BE showed only weak correlations. Correlations became significant with increasing BE-severity implying radiological alterations in several lobes. This indicates the importance of reporting both presence and extent of bronchiectasis on CT. Further research is warranted to refine the criteria for CT scoring of bronchiectasis and to determine the relevance of radiologically but not clinically detectible bronchiectasis and their possible implications for therapy in COPD patients.
Published: 2020

26. Allergen-Immuntherapie in der aktuellen Covid-19-Pandemie

Author: Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Poethig, Dagmar, Rabe, Klaus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, et al, University of Zurich, and Pfaar, Oliver
Subjects: 2733 Otorhinolaryngology, 10183 Swiss Institute of Allergy and Asthma Research, 10177 Dermatology Clinic, Immunology and Allergy, 610 Medicine & health
Published: 2020

27. Correction to 'ARIA guideline 2019: treatment of allergic rhinitis in the German health system' (Allergo Journal International, (2019), 28, 7, (255-276), 10.1007/s40629-019-00110-9)

Author: Klimek, Ludger, Bachert, Claus, Pfaar, Oliver, Becker, Sven, Bieber, Thomas, Brehler, Randolf, Buhl, Roland, Casper, Ingrid, Chaker, Adam, Czech, Wolfgang, Fischer, J. rg, Fuchs, Thomas, Gerstlauer, Michael, Hörmann, Karl, Jakob, Thilo, Jung, Kirsten, Kopp, Matthias V., Mahler, Vera, Merk, Hans, Mülleneisen, Norbert, Nemat, Katja, Rabe, Uta, Ring, Johannes, Saloga, Joachim, Schlenter, Wolfgang, Schmidt-Weber, Carsten, Seyfarth, Holger, Sperl, Annette, Spindler, Thomas, Staubach, Petra, Strieth, Sebastian, Treudler, Regina, Vogelberg, Christian, Wallrafen, Andrea, Wehrmann, Wolfgang, Wrede, Holger, Zuberbier, Torsten, Bedbrook, Anna, Canonica, Giorgio W., Cardona, Victoria, Casale, Thomas B., Czarlewski, Wienczylawa, Fokkens, Wytske J., Hamelmann, Eckard, Hellings, Peter W., Jutel, Marek, Larenas-Linnemann, D. sirée, Mullol, Joaquim, Papadopoulos, Nikolaos G., Toppila-Salmi, Sanna, Werfel, Thomas, Bousquet, Jean, Ear, Nose and Throat, and AII - Inflammatory diseases
Abstract: Correction to: Allergo J Int 2019 https://doi.org/10.1007/s40629-019-00110-9 Affiliation and disclaimer have been misrepresented and are hereby corrected: Vera Mahler: Affiliation: Med. Faculty, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Germany. Disclaimer: The views expressed in this.
Published: 2020

28. CAT score single item analysis in patients with COPD: results from COSYCONET

Author: J. Randerath Winfried, Pfeifer Michael, Kenn Klaus, Joachim H. Ficker, Gogol Manfred, Grohé Christian, Höffken Gerd, Zaklina Hinz, Julia Tobias, Henke Markus, Teschler Helmut, Welte Tobias, Benjamin Waschki, Buhl Roland, Paul W. Jones, Kirsten Anne-Marie, A. Katus Hugo, Taube Christian, Bewig Burkhard, Beate Polte, Kronsbein Juliane, Stubbe Beate, Bals Robert, Johanna I. Lutter, Sarah Marietta von Siemens, Lange Christoph, Vogelmeier Claus, Ellen Burmann, Wirtz Hubert, Kathrin Kahnert, Erich Traugott, Behr Jürgen, Birte Struck, Vivien Janke, Lenka Krabbe, Timmermann Hartmut, Wagner Ulrich, Anita Reichel, Sabine Michalewski, Gudrun Hübner, Seeger Werner, Doris Lehnert, Jany Berthold, Kropf-Sanchen Cornelia, Sandra Söhler, Jeanette Pieper, Ulrike Rieber, Peter Alter, Herth Felix, Zabel Peter, Andreas Stefan, Koczulla Rembert, Held Matthias, Tobias Welte, Franziska C. Trudzinski, Patricia Berger, Kahnert Kathrin, Jana Graf, Jürgen Behr, Rosalie Untsch, Rudolf A. Jörres, Kornelia Speth, Britta Markworth, Ewert Ralf, Gertraud Weiß, Hans-Ulrich Kauczor, Claus Vogelmeier, Katrin Schwedler, Katrin Wons, Bertram J. Jobst, Barbara Arikan, Margret Gleiniger, Henrik Watz, Watz Henrik, Studnicka Michael, Beate Schaufler, Diana Schottel, Sonja Rohweder, Robert Bals, Ilona Kietzmann, Virchow J. Christian, Burkhard Bewig, Hauck Rainer, and Michaela Schrade-Illmann
Subjects: Pulmonary and Respiratory Medicine, Percentile, medicine.medical_specialty, Medizin, Diagnostic Techniques, Respiratory System, Single item, CAT score, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Internal medicine, medicine, COPD, In patient, 030212 general & internal medicine, Lung function, Emphysema, business.industry, Regression analysis, Cat Score, Copd, medicine.disease, Exploratory factor analysis, respiratory tract diseases, 030228 respiratory system, Cohort, business
Abstract: The COPD Assessment Test (CAT) is in widespread use for the evaluation of patients with chronic obstructive pulmonary disease (COPD). We assessed whether the CAT items carry additional information beyond the sum score regarding COPD characteristics including emphysema. Patients of GOLD grades 1 to 4 from the COPD cohort COSYCONET (German COPD and Systemic Consequences - Comorbidities Network) with complete CAT data were included (n = 2270), of whom 493 had chest CT evaluated for the presence of emphysema. Comorbidities and lung function were assessed following standardised procedures. Cross-sectional data analysis was based on multiple regression analysis of the single CAT items against a panel of comorbidities, lung function, or CT characteristics (qualitative score, 15th percentile of mean lung density), with age, BMI and gender as covariates. This was supported by exploratory factor analysis. Regarding the relationship to comorbidities and emphysema, there were marked differences between CAT items, especially items 1 and 2 versus 3 to 8. This grouping was basically confirmed by factor analysis. Items 4 and 5, and to a lower degree 1, 2 and 6, appeared to be informative regarding the presence of emphysema, whereas the total score was not or less informative. Regarding comorbidities, similar findings as for the total CAT score were obtained for the modified Medical Research Council scale (mMRC) which was also informative regarding emphysema. Our findings suggest that the usefulness of the CAT can be increased if evaluated on the basis of single items which may be indicating the presence of comorbidities and emphysema.
Published: 2020

29. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

Author: Klimek, Ludger, Pfaar, Dr O., Worm, Margitta M., Eiwegger, Thomas, Hagemann, Jan, Ollert, Markus W., Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana O., Bavbek, S., Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, A., Vogelberg, Christian, Firinu, Davide, Kauppi, P., Kolios, Antonios G.A., Kothari, Akash, Matucci, Andrea, Palomares, Óscar, Szépfalusi, Zsolt, Hötzenecker, Wolfram, Rosenkranz, A. R., Bergmann, Karl Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen T.M., Darsow, Ulf G., Keil, Thomas, Kleine-Tebbe, Jörg, Lau, S., Maurer, Marcus, Merk, Hans Friedrich, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Klaus Friedrich, Rabe, Uta, Vogelmeier, Claus Franz, Biedermann, Tilo M., Jung, Kirsten, Schlenter, Wolfgang W., Ring, Johannnes, Chaker, Adam M., Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Mülleneisen, Norbert K., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolph B.S., Fuchs, Thomas, Tomazic, Peter Valentin, Aberer, Werner, Fink-Wagner, Antjie Henriette, Horak, Friedrich, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Pohl, Wolfgang, Roller-Wirnsberger, Regina Elisabeth, Spranger, Otto, Valenta, Rudolf, Akdis, Mübeccel, Matricardi, Paolo Maria, Spertini, François, Khaltaev, Nikolaï G., Michel, Jean Pierre, Nicod, Laurent Pierre, Schmid-Grendelmeier, Peter D., Idzko, Marco, Hamelmann, E., Jakob, Thilo, Werfel, Thomas Andreas, Wagenmann, Martin M., Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, François R., Schwarze, Jürgen, O'Mahony, Liam, Knol, Edward Frank, del Giacco, Stefano R., Chivato Pérez, T., Bousquet, Jean J., Zuberbier, Thorsten, Akdis, Cezmi A., Jutel, Marek, MACVIA-France, Montpellier, Centre de recherche en épidémiologie et santé des populations (CESP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
Subjects: SARS-CoV-2, [SDV]Life Sciences [q-bio], Benralizumab, Omalizumab, Dupilumab, Reslizumab, Covid-19, ComputingMilieux_MISCELLANEOUS, Mepolizumab, Telemedicine
Abstract: International audience
Published: 2020

30. Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA GroupA in cooperation with the Austrian ARIA GroupB, the Swiss ARIA GroupC, German Society for Applied Allergology (AEDA)D, German Society for Allergology and Clinical Immunology (DGAKI)E, Society for Pediatric Allergology (GPA)F in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHCG and the European Academy of Allergy and Clinical Immunology (EAACI)H

Author: Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Stute, Petra, Rabe, Klaus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert, Nemat, Katja, Czech, Wofgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink-Wagner, Antje, Horak, Friedrich, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Pohl, Wolfgang, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Mübecell, Akdis, Cezmi, Hoffmann-Sommergruber, Karin, Jutel, Marek, Matricardi, Paolo, Spertin, FranÇois, Khaltaev, Nikolai, Michel, Jean-Pierre, Nicod, Laurent, Schmid-Grendelmeier, Peter, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Gerstlauer, Michael, Vogelberg, Christian, Bousquet, Jean, and Zuberbier, Torsten
Subjects: 610 Medicine & health
Abstract: No abstract available.
Published: 2020
Full Text: View/download PDF

31. Allergen immunotherapy in the current COVID-19 pandemic - A position paper of the AeDA, ARIA, EAACI, DGAKI and GPA

Author: Klimek, Ludger, Pfaar, Dr O., Worm, Margitta M., Bergmann, Karl Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen T.M., Darsow, Ulf G., Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Mar, Merk, Hans Friedrich, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Stute, P., Rabe, Klaus, Rabe, Uta, Vogelmeier, Claus Franz, Biedermann, Tilo M., Jung, Kirsten, Schlenter, Wolfgang W., Ring, Johannnes, Chaker, Adam M., Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert K., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolph B.S., Fuchs, Thomas, Tomazic, Peter Valentin, Aberer, Werner, Fink-Wagner, Antjie Henriette, Horak, Friedrich, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Pohl, Wolfgang, Roller-Wirnsberger, Regina Elisabeth, Spranger, Otto, Valenta, Rudolf, Akdis, Mübeccel, Akdis, Cezmi A., Hoffmann-Sommergruber, Karin, Jutel, Marek, Matricardi, Paolo Maria, Spertini, François, Khaltaev, Nikolaï G., Michel, Jean Pierre, Nicod, Laurent, Schmid-Grendelmeier, Peter D., Hamelmann, E., Jakob, Thilo, Werfel, Thomas Andreas, Wagenmann, Martin, Taube, Christian, Gerstlauer, Michael, Vogelberg, Christian, Bousquet, Jean J., Zuberbier, Torsten, Rheinische Friedrich-Wilhelms-Universität Bonn, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: SLIT, [SDV]Life Sciences [q-bio], COVID-19, Antiviral immunity, SCIT, ComputingMilieux_MISCELLANEOUS, Allergen immunotherapy
Abstract: International audience
Published: 2020

32. Impact of donor lung quality on post-transplant recipient outcome in the LAS era in Eurotransplant

Author: Smits, Jacqueline M, Gottlieb, Jens, Verschuuren, Erik, Evrard, Patrick, Hoek, Rogier, Knoop, Christiane, Lang, György, Kwakkel-van Erp, Johanna M, Vos, Robin, Verleden, Geert, Rondelet, Benoît, Hoefer, Daniel, Langer, Frank, Schramm, Rene, Hoetzenecker, Konrad, van Kessel, Diana, Luijk, Bart, Seghers, Leonard, Deuse, Tobias, Buhl, Roland, Witt, Christian, Strelniece, Agita, Green, Dave, de Vries, Erwin, Laufer, Guenter, Van Raemdonck, Dirk, UCL - SSS/IREC/MEDA - Pôle de médecine aiguë, UCL - (MGD) Services des soins intensifs, UCL - (MGD) Service de chirurgie cardio-vasculaire et thoracique, and UCL - SSS/IREC/MONT - Pôle Mont Godinne
Abstract: The aim of this study was to investigate whether there is an impact of donation rates on the quality of lungs used for transplantation and whether donor lung quality affects post-transplant outcome in the current LAS era. All consecutive adult LTx performed in Eurotransplant (ET) between January 2012 and December 2016 were included (N=3053). Donors used for LTx in countries with high donation rate were younger (42% vs. 33% ≤ 45 years, p
Published: 2020

33. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemie

Author: Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thohomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Kothari, Akash, Matucci, Andrea, Palomares, Oscar, Szepfalusi, Zsolt, Pohl, Wolfgang, Hoetzenecker, Wolfram, Rosenkranz, Alexander R., Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Joerg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Moesges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Klaus F., Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ringa, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Muelleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink-Wagner, Antje-H, Horak, Fritz, Woehrl, Stefan, Niederberger-Leppin, Verena, Pali-Schoell, Isabella, Pohlg, Wolfgang, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Muebeccel, Matricardi, Paolo M., Spertini, Francois, Khaltaev, Nikolai, Michel, Jean-Pierre, Nicod, Laurent, Schmid-Grendelmeier, Peter, Idzko, Marco, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, Francois, Schwarze, Juergen, O'Mahony, Liam, Knol, Edward F., del Giacco, Stefano, Chivato Perez, Tomas, Bousquet, Jean, Zuberbier, Torsten, Akdis, Cezmi, and Jutel, Marek
Published: 2020

34. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)

Author: Pfaar, Oliver, Klimek, Ludger, Worm, Margitta M., Bergmann, Karl Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen T.M., Darsow, Ulf G., Keil, T., Kleine-Tebbe, Jörg, Lau, S., Maurer, Marcus, Merk, Hans Friedrich, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Stute, P., Rabe, K., Rabe, Uta, Vogelmeier, Claus Franz, Biedermann, Tilo M., Jung, K., Schlenter, Wolfgang W., Ring, J., Chaker, Adam M., Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert K., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolph B.S., Fuchs, Thomas, Tomazic, Peter Valentin, Aberer, Werner, Fink-Wagner, Antjie Henriette, Horak, Friedrich, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Pohl, Wolfgang, Roller-Wirnsberger, Regina Elisabeth, Spranger, Otto, Valenta, Rudolf, Akdis, Mübeccel, Akdis, Cezmi A., Hoffmann-Sommergruber, Karin, Jutel, Marek, Matricardi, Paolo Maria, Spertini, François, Khaltaev, Nikolaï G., Michel, Jean Pierre, Nicod, Laurent Pierre, Schmid-Grendelmeier, Peter D., Hamelmann, E., Jakob, Thilo, Werfel, Thomas Andreas, Wagenmann, Martin M., Taube, C., Gerstlauer, Michael, Vogelberg, Christian, Bousquet, Jean J., Zuberbier, Thorsten, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), FMC VIA LR, 371, avenue Doyen-Gaston-Giraud, 34295 Montpellier cedex 5, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), and Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)
Subjects: [SHS.LANGUE]Humanities and Social Sciences/Linguistics, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2020

35. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic:Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)

Author: Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Kothari, Akash, Matucci, Andrea, Palomares, Oscar, Szépfalusi, Zsolt, Pohl, Wolfgang, Hötzenecker, Wolfram, Rosenkranz, Alexander, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Klaus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Mülleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink-Wagner, Antje-Henriette, Horak, Fritz, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Mübecell, Matricardi, Paolo, Spertini, François, Khaltaev, Nicolai, Michel, Jean-Pierre, Nicod, Larent, Schmid-Grendelmeier, Peter, Idzko, Marco, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, Francois, Schwarze, Jürgen, O Mahony, Liam, Knol, Edward, Del Giacco, Stefano, Chivato Pérez, Tomás, Bousquet, Jean, Bedbrook, Anna, Zuberbier, Torsten, Akdis, Cezmi, Jutel, Marek, Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], Philipps Universität Marburg, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], The Hospital for sick children [Toronto] (SickKids), University of Toronto, Johannes Gutenberg - Universität Mainz (JGU), Luxembourg Institute of Health (LIH), University of Southern Denmark (SDU), Medizinische Universität Wien = Medical University of Vienna, Careggi University Hospital [Florence, Italie], Transylvania University, Ankara University School of Medicine [Turkey], Karolinska University Hospital [Stockholm], Karolinska Institutet [Stockholm], University hospital of Zurich [Zurich], Universität Zürich [Zürich] = University of Zurich (UZH), Guy's and St Thomas' Hospital [London], King‘s College London, National Technical University of Athens [Athens] (NTUA), University General Hospital ' Attikon ' [Athens, Greece], University of Athens Medical School [Athens], Universitätsklinikum Carl Gustav Carus Dresden, University of Cagliari, Harvard Medical School [Boston] (HMS), Österreichische Forschungsförderungsgesellschaft, Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Kepler University Hospital, Medizinische Universität Graz, Universitätsklinikum Bonn (UKB), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Helmholtz-Zentrum München (HZM), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), University of Würzburg = Universität Würzburg, Allergie- & Asthma-Zentrum Berlin Westend, Universitätsklinikum RWTH Aachen - University Hospital Aachen [Aachen, Germany] (UKA), RWTH Aachen University, Universität zu Köln, Clinical Research International Ltd [Hamburg, Germany] (CRI), University Medical Center [Mainz], Universität zu Lübeck [Lübeck], German Research Center for Environmental Health - Helmholtz Center München (GmbH), Universitätsklinikum Tübingen - University Hospital of Tübingen, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Asthma und Allergiezentrum [Leverkusen], Universitätsklinikum Münster [Munster, Germany], University of Göttingen - Georg-August-Universität Göttingen, Universität Wien, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), University of Geneva [Switzerland], Universitätsspital Zürich (USZ), Universität Bielefeld = Bielefeld University, Justus-Liebig-Universität Gießen (JLU), Medizinische Hochschule Hannover (MHH), Universitatsklinikum Dusseldorf, Dusseldorf Germany, Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Centre Hospitalier de Luxembourg [Luxembourg] (CHL), University of Edinburgh, APC Microbiome Ireland, University College Cork (UCC), University Medical Center [Utrecht], Universita degli Studi di Cagliari [Cagliari], University of San Pablo, Humboldt-Universität zu Berlin, Wroclaw Medical University [Wrocław, Pologne], and Technische Universität München [München] (TUM)
Subjects: benralizumab, SARS-CoV-2, COVID-19, mepolizumab, Benralizumab, Omalizumab, Dupilumab, reslizumab, Telemedicine, dupilumab, omalizumab, telemedicine, Reslizumab, Covid-19, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Mepolizumab
Abstract: International audience; Background: Since the beginning of the COVID-19 pandemic, the treatment of patients with allergic and atopy-associated diseases has faced major challenges. Recommendations for "social distancing" and the fear of patients becoming infected during a visit to a medical facility have led to a drastic decrease in personal doctor-patient contacts. This affects both acute care and treatment of the chronically ill. The immune response after SARS-CoV-2 infection is so far only insufficiently understood and could be altered in a favorable or unfavorable way by therapy with monoclonal antibodies. There is currently no evidence for an increased risk of a severe COVID-19 course in allergic patients. Many patients are under ongoing therapy with biologicals that inhibit type 2 immune responses via various mechanisms. There is uncertainty about possible immunological interactions and potential risks of these biologicals in the case of an infection with SARS-CoV-2.Materials and methods: A selective literature search was carried out in PubMed, Livivo, and the internet to cover the past 10 years (May 2010 - April 2020). Additionally, the current German-language publications were analyzed. Based on these data, the present position paper provides recommendations for the biological treatment of patients with allergic and atopy-associated diseases during the COVID-19 pandemic.Results: In order to maintain in-office consultation services, a safe treatment environment must be created that is adapted to the pandemic situation. To date, there is a lack of reliable study data on the care for patients with complex respiratory, atopic, and allergic diseases in times of an imminent infection risk from SARS-CoV-2. Type-2-dominant immune reactions, as they are frequently seen in allergic patients, could influence various phases of COVID-19, e.g., by slowing down the immune reactions. Theoretically, this could have an unfavorable effect in the early phase of a SARS-Cov-2 infection, but also a positive effect during a cytokine storm in the later phase of severe courses. However, since there is currently no evidence for this, all data from patients treated with a biological directed against type 2 immune reactions who develop COVID-19 should be collected in registries, and their disease courses documented in order to be able to provide experience-based instructions in the future.Conclusion: The use of biologicals for the treatment of bronchial asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and spontaneous urticaria should be continued as usual in patients without suspected infection or proven SARS-CoV-2 infection. If available, it is recommended to prefer a formulation for self-application and to offer telemedical monitoring. Treatment should aim at the best possible control of difficult-to-control allergic and atopic diseases using adequate rescue and add-on therapy and should avoid the need for systemic glucocorticosteroids. If SARS-CoV-2 infection is proven or reasonably suspected, the therapy should be determined by weighing the benefits and risks individually for the patient in question, and the patient should be involved in the decision-making. It should be kept in mind that the potential effects of biologicals on the immune response in COVID-19 are currently not known. Telemedical offers are particularly desirable for the acute consultation needs of suitable patients.
Published: 2020

36. Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA Group$^{A}$ in cooperation with the Austrian ARIA Group$^{B}$, the Swiss ARIA Group$^{C}$, German Society for Applied Allergology (AEDA)$^{D}$, German Society for Allergology and Clinical Immunology (DGAKI)$^{E}$, Society for Pediatric Allergology (GPA)$^{F}$ in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHC$^{G}$ and the European Academy of Allergy and Clinical Immunology (EAACI)$^{H}$

Author: Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Stute, Petra, Rabe, Klaus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert, Nemat, Katja, Czech, Wofgang, et al, and University of Zurich
Subjects: 10183 Swiss Institute of Allergy and Asthma Research, 10177 Dermatology Clinic, 610 Medicine & health
Published: 2020

37. Soluble Triggering Receptor Expressed on Myeloid Cells 1 in lung cancer

Author: Kuemmel, Andreas, Alflen, Astrid, Schmidt, Lars Henning, Sebastian, Martin, Wiewrodt, Rainer, Schulze, Arik Bernard, Buhl, Roland, and Radsak, Markus
Subjects: Male, Lung Neoplasms, lcsh:R, 610 Medizin, lcsh:Medicine, Comorbidity, Middle Aged, Prognosis, Survival Analysis, Article, Triggering Receptor Expressed on Myeloid Cells-1, Pleural Effusion, Malignant, Carcinoma, Bronchogenic, Treatment Outcome, 610 Medical sciences, Humans, Regression Analysis, Female, lcsh:Q, ddc:610, Neoplasm Metastasis, lcsh:Science, Biomarkers, Aged, Proportional Hazards Models
Abstract: Soluble Triggering Receptor Expressed on Myeloid Cells 1 (sTREM-1) can be found in the sera of patients with infectious, autoimmune and malignant diseases. The primary objective of this study was to investigate the prognostic significance of sTREM-1 in lung cancer patients. We analyzed the sera of 164 patients with lung cancer of all histologies and all stages at the time of diagnosis. We employed an ELISA using the anti-TREM-1 clone 6B1.1G12 mAb and recombinant human TREM-1. Patient data was collected retrospectively by chart review. In ROC-analysis, a sTREM-1 serum level of 163.1 pg/ml showed the highest Youden-Index. At this cut-off value sTREM-1 was a marker of short survival in patients with NSCLC (median survival 8.5 vs. 13.3 months, p = 0.04). A Cox regression model showed stage (p
Published: 2018

38. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting

Author: Steinmetz,Karl-Otto, Abenhardt,Birgit, Pabst,Stefan, HÃ¤nsel,Michaela, Kondla,Anke, Bayer,Valentina, and Buhl,Roland
Subjects: International Journal of Chronic Obstructive Pulmonary Disease
Abstract: Karl-Otto Steinmetz,1 Birgit Abenhardt,2 Stefan Pabst,3 Michaela Hänsel,4 Anke Kondla,5 Valentina Bayer,6 Roland Buhl71LungCenter Darmstadt, Darmstadt, Germany; 2Pulmonary Practice, Heidelberg, Germany; 3Lung Center, Bonn-Duisdorf, Germany; 4TA Respiratory/Biosimilars, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 5Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; 6Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 7Pulmonary Department, Johannes Gutenberg University Hospital Mainz, Mainz, GermanyBackground: Patients with chronic obstructive pulmonary disease (COPD) show signs of reduced physical activity from the early stages of the disease, impacting morbidity and mortality. Data suggest treatment with tiotropium, a long-acting muscarinic antagonist, and olodaterol, a long-acting ß2-agonist (LABA), as monotherapies and in combination, increases exercise capacity. This study assessed the effects of fixed-dose tiotropium/olodaterol (delivered via Respimat®,) on physical function in Global Initiative for Chronic Obstructive Lung Disease A–D patients requiring long-acting dual bronchodilation treatment in a real-world setting.Methods: This open-label, single arm, noninterventional study measured changes in physical function in COPD patients treated with tiotropium/olodaterol 5/5 μg for approximately 6 weeks (between Visit 1 [baseline] and Visit 2). Primary end point was therapeutic success, defined as a minimum 10-point increase in Physical Functioning Questionnaire (PF-10) score. Secondary end points included change in PF-10 from Visit 1 to Visit 2, the patient’s general condition (measured by Physician’s Global Evaluation score) at Visit 1 and Visit 2, and patient satisfaction with treatment delivered via the Respimat®, device (assessed by Patient Satisfaction Questionnaire) at study end.Results: Therapeutic success was observed in 51.5% of 1578 patients (95% confidence interval [CI] 49.0, 54.0) after approximately 6 weeks of treatment with tiotropium/olodaterol. Mean change in PF-10 score between Visit 1 and Visit 2 was 11.6 points (95% CI 10.7, 12.6). Patient general condition improved as indicated by a general improvement in scores between visits. Most patients were very satisfied or satisfied with tiotropium/olodaterol treatment (82.5%), inhalation (87.5%), and handling of Respimat®, (85.2%). One percent of patients reported an investigator-defined drug-related adverse events (AE).Conclusion: Tiotropium/olodaterol treatment improved physical functioning in COPD patients. An associated increase in patient general condition was observed. Most patients were very satisfied or satisfied with tiotropium/olodaterol treatment, inhaling, and handling of the Respimat®, device. No unexpected drug-related AE occurred.Keywords: tiotropium, olodaterol, chronic obstructive pulmonary disease, physical activity, noninterventional study &nbsp
Published: 2019

39. Future perspectives of anticholinergics for the treatment of asthma in adults and children

Author: Buhl,Roland and Hamelmann,Eckard
Subjects: Therapeutics and Clinical Risk Management, humanities, respiratory tract diseases
Abstract: Roland Buhl,1 Eckard Hamelmann2,3 1Pulmonary Department, Johannes Gutenberg University Hospital Mainz, Mainz, Germany; 2Children’s Center Bethel, Evangelic Hospital Bethel, Department of Pediatrics, Bielefeld, Germany; 3University Children’s Hospital, Allergy Center Ruhr, Ruhr University Bochum, Bochum, Germany Abstract: Despite major advances in therapeutic interventions and the availability of detailed treatment guidelines, a high proportion of patients with symptomatic asthma remain uncontrolled. Asthma management is largely guided by the Global Initiative for Asthma (GINA) strategy and is based on a backbone of inhaled corticosteroid (ICS) therapy with the use of additional therapies to achieve disease control. Inhaled long-acting bronchodilators alone and in combination are the preferred add-on treatment options. Although long-acting muscarinic antagonists (LAMAs) are a relatively recent addition to disease management recommendations for asthma, tiotropium has been extensively studied in a large clinical trial program. In Europe and the United States, tiotropium is approved for patients aged ≥6 years and uncontrolled on medium- to high-dose ICS/long-acting β2-agonists at GINA Steps 4 and 5 with a history of exacerbations. Evidence supports the efficacy of tiotropium Respimat® in adults in terms of lung function and asthma control, with a safety profile comparable with that of placebo across a range of asthma severities. Similarly, clinical trials in patients aged 1–17 years have shown improvements in lung function and trends toward improved asthma control. Furthermore, its efficacy makes tiotropium relatively easy to incorporate into routine clinical practice, irrespective of allergic status and without the need for patient phenotyping. Tiotropium is a cost-effective treatment that may offer an important alternative to other, more expensive add-on therapies. This review discusses the potential future position of LAMAs in clinical practice by considering the continuously evolving evidence. Prominence is given to tiotropium, the only LAMA supported by a structured clinical trial program in asthma to date, while also considering other recommended treatment options for patients with uncontrolled asthma. The importance of effective patient/caregiver–clinician communication and shared decision-making in enhancing treatment adherence is also highlighted. Keywords: asthma, anticholinergic, tiotropium, LAMA, asthma management, adherence, pediatric asthma
Published: 2019

40. Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort

Author: F.C. Trudzinski, K. Kahnert, C.F. Vogelmeier, P. Alter, F. Seiler, S. Fähndrich, H. Watz, T. Welte, T. Speer, S. Zewinger, F. Biertz, H.-U. Kauczor, R.A. Jörres, R. Bals, Andreas Stefan, Bals Robert, Behr Jürgen, Kahnert Kathrin, Bewig Burkhard, Buhl Roland, Ewert Ralf, Stubbe Beate, Ficker Joachim H, Gogol Manfred, Grohé Christian, Hauck Rainer, Held Matthias, Jany Berthold, Henke Markus, Herth Felix, Höffken Gerd, Katus Hugo A, Kirsten Anne-Marie, Watz Henrik, Koczulla Rembert, Kenn Klaus, Kronsbein Juliane, Kropf-Sanchen Cornelia, Lange Christoph, Zabel Peter, Pfeifer Michael, Randerath Winfried J, null eeger Werner, Studnicka Michael, Taube Christian, Teschler Helmut, Timmermann Hartmut, Virchow J. Christian, Vogelmeier Claus, Wagner Ulrich, Welte Tobias, and Wirtz Hubert
Subjects: Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Exacerbation, Partial Pressure, Medizin, Renal function, Comorbidity, Acid-Base Imbalance, Kidney Function Tests, Risk Assessment, Cohort Studies, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, DLCO, Diffusing capacity, Internal medicine, Forced Expiratory Volume, medicine, Humans, Respiratory function, 030212 general & internal medicine, Aged, COPD, Carbon Monoxide, business.industry, Middle Aged, medicine.disease, respiratory tract diseases, Respiratory Function Tests, Cross-Sectional Studies, 030228 respiratory system, Cohort, Cardiology, Disease Progression, Pulmonary Diffusing Capacity, Female, Blood Gas Analysis, Risk assessment, business, Glomerular Filtration Rate
Abstract: Rationale Alterations of acid-base metabolism are an important outcome predictor in acute exacerbations of COPD, whereas sufficient metabolic compensation and adequate renal function are associated with decreased mortality. In stable COPD there is, however, only limited information on the combined role of acid-base balance, blood gases, renal and respiratory function on exacerbation risk grading. Methods We used baseline data of the COPD cohort COSYCONET, applying linear and logistic regression analyses, the results of which were implemented into a comprehensive structural equation model. As most informative parameters it comprised the estimated glomerular filtration rate (eGFR), lung function defined via forced expiratory volume in 1 s (FEV1), intrathoracic gas volume (ITGV) and (diffusing capacity for carbon monoxide (DLCO), moreover arterial oxygen content (CaO2), partial pressure of oxygen (PaCO2), base exess (BE) and exacerbation risk according to GOLD criteria. All measures were adjusted for age, gender, body-mass index, the current smoking status and pack years. Results 1506 patients with stable COPD (GOLD grade 1–4; mean age 64.5 ± 8.1 y; mean FEV1 54 ± 18 %predicted, mean eGFR 82.3 ± 16.9 mL/min/1.73 m2) were included. BE was linked to eGFR, lung function and PaCO2 and played a role as indirect predictor of exacerbation risk via these measures; moreover, eGFR was directly linked to exacerbation risk. These associations remained significant after taking into account medication (diuretics, oral and inhaled corticosteroids), whereby corticosteroids had effects on exacerbation risk and lung function, diuretics on eGFR, BE and lung function. Conclusion Even in stable COPD acid-base metabolism plays a key integrative role in COPD risk assessment despite rather small deviations from normality. It partially mediates the effects of impairments in kidney function, which are also directly linked to exacerbation risk.
Published: 2019

41. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases: Review

Author: Schünemann, Holger J., Yiallouros, Panayiotis K., Bousquet, J. Jean, Togias, Alkis, Erhola, Marina, Hellings, Peter W., Zuberbier, Torsten, Agache, Ioana, Ansotegui, Ignacio J., Anto, Josep M., Bachert, Claus, Becker, Sven, Bedolla-Barajas, Martin, Bewick, Michael, Bosnic-Anticevich, Sinthia, Bosse, Isabelle, Boulet, Louis P., Bourrez, Jean Marc, Brusselle, Guy, Chavannes, Niels, Costa, Elisio, Cruz, Alvaro A., Czarlewski, Wienczyslawa, Fokkens, Wytske J., Fonseca, Joao A., Gaga, Mina, Haahtela, Tari, Illario, Maddalena, Klimek, Ludger, Kuna, Piotr, Kvedariene, Violeta, Le, L. T. T., Larenas-Linnemann, Desiree, Laune, Daniel, Lourenço, Olga M., Menditto, Enrica, Mullol, Joaquin, Okamoto, Yashitaka, Papadopoulos, Nikos, Pham-Thi, Nhân, Picard, Robert, Pinnock, Hilary, Roche, Nicolas, Roller-Wirnsberger, Regina E., Rolland, Christine, Samolinski, Boleslaw, Sheikh, Aziz, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Valiulis, Arunas, Valovirta, Erkka, Vasankari, Tuula, Ventura, Maria-Teresa, Walker, Samantha, Williams, Sian, Akdis, Cezmi A., Annesi-Maesano, Isabella, Arnavielhe, Sylvie, Basagana, Xavier, Bateman, Eric, Bedbrook, Anna, Bennoor, K. S., Benveniste, Samuel, Bergmann, Karl C., Bialek, Slawomir, Billo, Nils, Bindslev-Jensen, Carsten, Bjermer, Leif, Blain, Hubert, Bonini, Mateo, Bonniaud, Philippe, Bouchard, Jacques, Briedis, Vitalis, Brightling, Christofer E., Brozek, Jan, Buhl, Roland, Buonaiuto, Roland, Canonica, Giorgo W., Cardona, Victoria, Carriazo, Ana M., Carr, Warner, Cartier, Christine, Casale, Thomas, Cecchi, Lorenzo, Cepeda Sarabia, Alfonso M., Chkhartishvili, Eka, Chu, Derek K., Cingi, Cemal, Colgan, Elaine, de Sousa, Jaime Correia, Courbis, Anne Lise, Custovic, Adnan, Cvetkosvki, Biljana, D’Amato, Gennaro, da Silva, Jane, Dantas, Carina, Dokic, Dejand, Dauvilliers, Yves, Dedeu, Antoni, De Feo, Giulia, Devillier, Philippe, Di Capua, Stefania, Dykewickz, Marc, Dubakiene, Ruta, Ebisawa, Motohiro, El-Gamal, Yaya, Eller, Esben, Emuzyte, Regina, Farrell, John, Fink-Wagner, Antjie, Fiocchi, Alessandro, Fontaine, Jean F., Gemicioğlu, Bilun, Schmid-Grendelmeir, Peter, Gamkrelidze, Amiran, Garcia-Aymerich, Judith, Gomez, Maximiliano, González Diaz, Sandra, Gotua, Maia, Guldemond, Nick A., Guzmán, Maria-Antonieta, Hajjam, Jawad, O’B Hourihane, John, Humbert, Marc, Iaccarino, Guido, Ierodiakonou, Despo, Ivancevich, Juan C., Joos, Guy, Jung, Ki-Suck, Jutel, Marek, Kaidashev, Igor, Kalayci, Omer, Kardas, Przemyslaw, Keil, Thomas, Khaitov, Mussa, Khaltaev, Nikolai, Kleine-Tebbe, Jorg, Kowalski, Marek L., Kritikos, Vicky, Kull, Inger, Leonardini, Lisa, Lieberman, Philip, Lipworth, Brian, Lodrup Carlsen, Karin C., Loureiro, Claudia C., Louis, Renaud, Mair, Alpana, Marien, Gert, Mahboub, Bassam, Malva, Joao, Manning, Patrick, De Manuel Keenoy, Esteban, Marshall, Gailen D., Masjedi, Mohamed R., Maspero, Jorge F., Mathieu-Dupas, Eve, Matricardi, Poalo M., Melén, Eric, Melo-Gomes, Elisabete, Meltzer, Eli O., Mercier, Jacques, Miculinic, Neven, Mihaltan, Florin, Milenkovic, Branislava, Moda, Giuliana, Mogica-Martinez, Maria-Dolores, Mohammad, Yousser, Montefort, Steve, Monti, Ricardo, Morais-Almeida, Mario, Mösges, Ralf, Münter, Lars, Muraro, Antonella, Murray, Ruth, Naclerio, Robert, Napoli, Luigi, Namazova-Baranova, Leila, Neffen, Hugo, Nekam, Kristoff, Neou, Angelo, Novellino, Enrico, Nyembue, Dieudonné, O’Hehir, Robin, Ohta, Ken, Okubo, Kimi, Onorato, Gabrielle, Ouedraogo, Solange, Pali-Schöll, Isabella, Palkonen, Susanna, Panzner, Peter, Park, Hae-Sim, Pépin, Jean-Louis, Pereira, Ana-Maria, Pfaar, Oliver, Paulino, Ema, Phillips, Jim, Plavec, Davor, Popov, Ted A., Portejoie, Fabienne, Price, David, Prokopakis, Emmanuel P., Pugin, Benoit, Raciborski, Filip, Rajabian-Söderlund, Rojin, Reitsma, Sietze, Rodo, Xavier, Romano, Antonino, Rosario, Nelson, Rottem, Menahenm, Ryan, Dermot, Salimäki, Johanna, Sanchez-Borges, Mario M., Sisul, Juan-Carlos, Solé, Dirceu, Somekh, David, Sooronbaev, Talant, Sova, Milan, Spranger, Otto, Stellato, Cristina, Stelmach, Rafael, Suppli Ulrik, Charlotte, Thibaudon, Michel, To, Teresa, Todo-Bom, Ana, Tomazic, Peter V., Valero, Antonio A., Valenta, Rudolph, Valentin-Rostan, Marylin, van der Kleij, Rianne, Vandenplas, Olivier, Vezzani, Giorgio, Viart, Frédéric, Viegi, Giovanni, Wallace, Dana, Wagenmann, Martin, Wang, De Y., Waserman, Susan, Wickman, Magnus, Williams, Dennis M., Wong, Gary, Wroczynski, Piotr, Yorgancioglu, Arzu, Yusuf, Osman M., Zar, Heahter J., Zeng, Stéphane, Zernotti, Mario, Zhang, Luo, Zhong, Nan S., Zidarn, Mihaela, Bousquet, J., Hellings, P. W., Aberer, W., Agache, I., Akdis, C. A., Akdis, M., Aliberti, M. R., Almeida, R., Amat, F., Angles, R., Annesi-Maesano, I., Ansotegui, I. J., Anto, J. M., Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H., Avolio, F., Bacci, E., Bachert, C., Baiardini, I., Barbara, C., Barbagallo, M., Baroni, I., Barreto, B. A., Basagana, X., Bateman, E. D., Bedolla-Barajas, M., Bedbrook, A., Bewick, M., Beghé, B., Bel, E. H., Bergmann, K. C., Benson, M., Bertorello, L., Białoszewski, A. Z., Bieber, T., Bialek, S., Bindslev-Jensen, C., Bjermer, L., Blain, H., Blasi, F., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., the ARIA Study Group, the MASK Study Group, Briedis, Vitalis, uBibliorum, Yiallouros, Panayiotis K. [0000-0002-8339-9285], Costa, Elisio [0000-0003-1158-1480], Kritikos, Vicky [0000-0003-3955-0002], Gaga, Mina [0000-0002-9949-6012], Prokopakis, Emmanuel P. [0000-0002-1208-1990], Togias, Alkis [0000-0001-9009-5717], Erhola, Marina [0000-0002-1364-9023], Bosnic-Anticevich, Sinthia [0000-0001-5077-8329], Lourenço, Olga M. [0000-0002-8401-5976], Ierodiakonou, Despo [0000-0002-7862-2016], Health Services Management & Organisation (HSMO), Obstetrics & Gynecology, Universidade do Minho, Laboratoire de Génie Informatique et Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Bousquet, J. J., Schunemann, H. J., Togias, A., Erhola, M., Hellings, P. W., Zuberbier, T., Agache, I., Ansotegui, I. J., Anto, J. M., Bachert, C., Becker, S., Bedolla-Barajas, M., Bewick, M., Bosnic-Anticevich, S., Bosse, I., Boulet, L. P., Bourrez, J. M., Brusselle, G., Chavannes, N., Costa, E., Cruz, A. A., Czarlewski, W., Fokkens, W. J., Fonseca, J. A., Gaga, M., Haahtela, T., Illario, M., Klimek, L., Kuna, P., Kvedariene, V., Le, L. T. T., Larenas-Linnemann, D., Laune, D., Lourenco, O. M., Menditto, E., Mullol, J., Okamoto, Y., Papadopoulos, N., Pham-Thi, N., Picard, R., Pinnock, H., Roche, N., Roller-Wirnsberger, R. E., Rolland, C., Samolinski, B., Sheikh, A., Toppila-Salmi, S., Tsiligianni, I., Valiulis, A., Valovirta, E., Vasankari, T., Ventura, M. -T., Walker, S., Williams, S., Akdis, C. A., Annesi-Maesano, I., Arnavielhe, S., Basagana, X., Bateman, E., Bedbrook, A., Bennoor, K. S., Benveniste, S., Bergmann, K. C., Bialek, S., Billo, N., Bindslev-Jensen, C., Bjermer, L., Blain, H., Bonini, M., Bonniaud, P., Bouchard, J., Briedis, V., Brightling, C. E., Brozek, J., Buhl, R., Buonaiuto, R., Canonica, G. W., Cardona, V., Carriazo, A. M., Carr, W., Cartier, C., Casale, T., Cecchi, L., Cepeda Sarabia, A. M., Chkhartishvili, E., Chu, D. K., Cingi, C., Colgan, E., De Sousa, J. C., Courbis, A. L., Custovic, A., Cvetkosvki, B., Damato, G., Da Silva, J., Dantas, C., Dokic, D., Dauvilliers, Y., Dedeu, A., De Feo, G., Devillier, P., Di Capua, S., Dykewickz, M., Dubakiene, R., Ebisawa, M., El-Gamal, Y., Eller, E., Emuzyte, R., Farrell, J., Fink-Wagner, A., Fiocchi, A., Fontaine, J. F., Gemicioglu, B., Schmid-Grendelmeir, P., Gamkrelidze, A., Garcia-Aymerich, J., Gomez, M., Diaz, S. G., Gotua, M., Guldemond, N. A., Guzman, M. -A., Hajjam, J., O'Hourihane, J. B., Humbert, M., Iaccarino, G., Ierodiakonou, D., Ivancevich, J. C., Joos, G., Jung, K. -S., Jutel, M., Kaidashev, I., Kalayci, O., Kardas, P., Keil, T., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Kowalski, M. L., Kritikos, V., Kull, I., Leonardini, L., Lieberman, P., Lipworth, B., Lodrup Carlsen, K. C., Loureiro, C. C., Louis, R., Mair, A., Marien, G., Mahboub, B., Malva, J., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., Maspero, J. F., Mathieu-Dupas, E., Matricardi, P. M., Melen, E., Melo-Gomes, E., Meltzer, E. O., Mercier, J., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda, G., Mogica-Martinez, M. -D., Mohammad, Y., Montefort, S., Monti, R., Morais-Almeida, M., Mosges, R., Munter, L., Muraro, A., Murray, R., Naclerio, R., Napoli, L., Namazova-Baranova, L., Neffen, H., Nekam, K., Neou, A., Novellino, E., Nyembue, D., O'Hehir, R., Ohta, K., Okubo, K., Onorato, G., Ouedraogo, S., Pali-Scholl, I., Palkonen, S., Panzner, P., Park, H. -S., Pepin, J. -L., Pereira, A. -M., Pfaar, O., Paulino, E., Phillips, J., Plavec, D., Popov, T. A., Portejoie, F., Price, D., Prokopakis, E. P., Pugin, B., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Rodo, X., Romano, A., Rosario, N., Rottem, M., Ryan, D., Salimaki, J., Sanchez-Borges, M. M., Sisul, J. -C., Sole, D., Somekh, D., Sooronbaev, T., Sova, M., Spranger, O., Stellato, C., Stelmach, R., Ulrik, C. S., Thibaudon, M., To, T., Todo-Bom, A., Tomazic, P. V., Valero, A. A., Valenta, R., Valentin-Rostan, M., Van Der Kleij, R., Vandenplas, O., Vezzani, G., Viart, F., Viegi, G., Wallace, D., Wagenmann, M., Wang, D. Y., Waserman, S., Wickman, M., Williams, D. M., Wong, G., Wroczynski, P., Yiallouros, P. K., Yorgancioglu, A., Yusuf, O. M., Zar, H. J., Zeng, S., Zernotti, M., Zhang, L., Zhong, N. S., Zidarn, M., UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, and UCL - (MGD) Service de pneumologie
Subjects: Allergy, IMPACT, Respiratory Medicine and Allergy, ARIA Study Group, Health care transformation, Care pathways, Rhinitis, ARIA, MASK, POLLAR, Review, GUIDELINES, Medical and Health Sciences, PATIENT-CARE, 0302 clinical medicine, immune system diseases, 11. Sustainability, Health care, Medicine and Health Sciences, Outras Ciências Médicas [Ciências Médicas], Immunology and Allergy, Medicine, 030212 general & internal medicine, mHealth, health care economics and organizations, Lungmedicin och allergi, Rhinitis, Self-management, 616.2 [udc], Environmental exposure, POLLAR, 3. Good health, CHRONIC RESPIRATORY-DISEASES, Care pathways, HEALTH, Life Sciences & Biomedicine, Pulmonary and Respiratory Medicine, SEASONAL ALLERGIC RHINITIS, medicine.medical_specialty, animal structures, MASK, Health care transformation, EUROPEAN INNOVATION PARTNERSHIP, ARIA, Immunology, Health literacy, 03 medical and health sciences, INTERMITTENT, BUDESONIDE-FORMOTEROL, As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement, Air pollutants, adverse effects, Air pollution, Asthma, physiopathology, physiopathology [In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body], Patient participation, SELF-MANAGEMENT, MASK Study Group, Ciências Médicas::Outras Ciências Médicas, udc:616.2, Care pathway, Science & Technology, business.industry, RC581-607, medicine.disease, respiratory tract diseases, Integrated care, 030228 respiratory system, 13. Climate action, Family medicine, Immunologic diseases. Allergy, Clinical Medicine, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted “patient activation”, (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement., Partly funded by POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), and ARIA.
Published: 2019

42. MOESM1 of Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases

Author: J. Bousquet, SchĂźnemann, Holger, Togias, Alkis, Erhola, Marina, Hellings, Peter, Zuberbier, Torsten, Agache, Ioana, Ansotegui, Ignacio, Anto, Josep, Bachert, Claus, Becker, Sven, Bedolla-Barajas, Martin, Bewick, Michael, Sinthia Bosnic-Anticevich, Bosse, Isabelle, Boulet, Louis, Bourrez, Jean, Brusselle, Guy, Chavannes, Niels, Elisio Costa, Cruz, Alvaro, Wienczyslawa Czarlewski, Fokkens, Wytske, Joao Fonseca, Gaga, Mina, Tari Haahtela, Illario, Maddalena, Klimek, Ludger, Kuna, Piotr, Kvedariene, Violeta, L. Le, Larenas-Linnemann, Desiree, Laune, Daniel, LourenĂ§O, Olga, Menditto, Enrica, Joaquin Mullol, Yashitaka Okamoto, Papadopoulos, Nikos, NhĂ˘N Pham-Thi, Picard, Robert, Pinnock, Hilary, Roche, Nicolas, Roller-Wirnsberger, Regina, Rolland, Christine, Boleslaw Samolinski, Sheikh, Aziz, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Arunas Valiulis, Valovirta, Erkka, Vasankari, Tuula, Maria-Teresa Ventura, Walker, Samantha, Williams, Sian, Akdis, Cezmi, Annesi-Maesano, Isabella, Arnavielhe, Sylvie, Basagana, Xavier, Bateman, Eric, Bedbrook, Anna, K. Bennoor, Benveniste, Samuel, Bergmann, Karl, Slawomir Bialek, Billo, Nils, Bindslev-Jensen, Carsten, Bjermer, Leif, Blain, Hubert, Bonini, Mateo, Bonniaud, Philippe, Bouchard, Jacques, Briedis, Vitalis, Brightling, Christofer, Brozek, Jan, Buhl, Roland, Buonaiuto, Roland, Giorgo Canonica, Cardona, Victoria, Carriazo, Ana, Carr, Warner, Cartier, Christine, Casale, Thomas, Cecchi, Lorenzo, Sarabia, Alfonso Cepeda, Chkhartishvili, Eka, Chu, Derek, Cingi, Cemal, Colgan, Elaine, Sousa, Jaime, Courbis, Anne, Custovic, Adnan, Cvetkosvki, Biljana, DâAmato, Gennaro, Silva, Jane, Dantas, Carina, Dejand Dokic, Dauvilliers, Yves, Dedeu, Antoni, Feo, Giulia, Devillier, Philippe, Capua, Stefania, Dykewickz, Marc, Dubakiene, Ruta, Ebisawa, Motohiro, Yaya El-Gamal, Eller, Esben, Emuzyte, Regina, Farrell, John, Antjie Fink-Wagner, Fiocchi, Alessandro, Fontaine, Jean, Bilun GemicioÄLu, Schmid-Grendelmeir, Peter, Gamkrelidze, Amiran, Garcia-Aymerich, Judith, Gomez, Maximiliano, Diaz, Sandra GonzĂĄlez, Gotua, Maia, Guldemond, Nick, Maria-Antonieta GuzmĂĄn, Hajjam, Jawad, Hourihane, John OâB, Humbert, Marc, Iaccarino, Guido, Despo Ierodiakonou, Ivancevich, Juan, Joos, Guy, Ki-Suck Jung, Jutel, Marek, Kaidashev, Igor, Kalayci, Omer, Przemyslaw Kardas, Keil, Thomas, Mussa Khaitov, Khaltaev, Nikolai, Kleine-Tebbe, Jorg, Kowalski, Marek, Kritikos, Vicky, Kull, Inger, Leonardini, Lisa, Lieberman, Philip, Lipworth, Brian, Carlsen, Karin Lodrup, Loureiro, Claudia, Louis, Renaud, Alpana Mair, Marien, Gert, Mahboub, Bassam, Joao Malva, Manning, Patrick, Keenoy, Esteban Manuel, Gailen Marshall, Masjedi, Mohamed, Maspero, Jorge, Mathieu-Dupas, Eve, Poalo Matricardi, MelĂŠn, Eric, Melo-Gomes, Elisabete, Meltzer, Eli, Mercier, Jacques, Miculinic, Neven, Mihaltan, Florin, Milenkovic, Branislava, Moda, Giuliana, Maria-Dolores Mogica-Martinez, Yousser Mohammad, Montefort, Steve, Monti, Ricardo, Morais-Almeida, Mario, MĂśsges, Ralf, MĂźnter, Lars, Muraro, Antonella, Murray, Ruth, Naclerio, Robert, Napoli, Luigi, Namazova-Baranova, Leila, Neffen, Hugo, Kristoff Nekam, Neou, Angelo, Novellino, Enrico, DieudonnĂŠ Nyembue, OâHehir, Robin, Ohta, Ken, Okubo, Kimi, Onorato, Gabrielle, Ouedraogo, Solange, Pali-SchĂśll, Isabella, Palkonen, Susanna, Panzner, Peter, Hae-Sim Park, Jean-Louis PĂŠpin, Ana-Maria Pereira, Pfaar, Oliver, Paulino, Ema, Phillips, Jim, Plavec, Davor, Popov, Ted, Portejoie, Fabienne, Price, David, Prokopakis, Emmanuel, Benoit Pugin, Raciborski, Filip, Rojin Rajabian-SĂśderlund, Reitsma, Sietze, Rodo, Xavier, Romano, Antonino, Rosario, Nelson, Menahenm Rottem, Ryan, Dermot, SalimĂ¤Ki, Johanna, Sanchez-Borges, Mario, Juan-Carlos Sisul, Dirceu SolĂŠ, Somekh, David, Talant Sooronbaev, Sova, Milan, Spranger, Otto, Stellato, Cristina, Stelmach, Rafael, Ulrik, Charlotte Suppli, Thibaudon, Michel, To, Teresa, Todo-Bom, Ana, Tomazic, Peter, Valero, Antonio, Valenta, Rudolph, Valentin-Rostan, Marylin, Kleij, Rianne, Vandenplas, Olivier, Vezzani, Giorgio, FrĂŠdĂŠric Viart, Viegi, Giovanni, Wallace, Dana, Wagenmann, Martin, Wang, De, Waserman, Susan, Wickman, Magnus, Williams, Dennis, Wong, Gary, Wroczynski, Piotr, Yiallouros, Panayiotis, Yorgancioglu, Arzu, Yusuf, Osman, Heahter Zar, StĂŠphane Zeng, Zernotti, Mario, Zhang, Luo, Zhong, Nan, and Zidarn, Mihaela
Abstract: Additional file 1. The MASK Study Group.
Published: 2019
Full Text: View/download PDF

43. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases

Author: Bousquet, J. Jean Schunemann, Holger J. Togias, Alkis and Erhola, Marina Hellings, Peter W. Zuberbier, Torsten Agache, Ioana Ansotegui, Ignacio J. Anto, Josep M. Bachert, Claus and Becker, Sven Bedolla-Barajas, Martin Bewick, Michael and Bosnic-Anticevich, Sinthia Bosse, Isabelle Boulet, Louis P. and Bourrez, Jean Marc Brusselle, Guy Chavannes, Niels Costa, Elisio Cruz, Alvaro A. Czarlewski, Wienczyslawa Fokkens, Wytske J. Fonseca, Joao A. Gaga, Mina Haahtela, Tari and Illario, Maddalena Klimek, Ludger Kuna, Piotr Kvedariene, Violeta Le, L. T. T. Larenas-Linnemann, Desiree Laune, Daniel Lourenco, Olga M. Menditto, Enrica Mullo, Joaquin and Okamoto, Yashitaka Papadopoulos, Nikos Nhan Pham-Thi Picard, Robert Pinnock, Hilary Roche, Nicolas Roller-Wirnsberger, Regina E. Rolland, Christine Samolinski, Boleslaw Sheikh, Aziz Toppila-Salmi, Sanna Tsiligianni, Ioanna Valiulis, Arunas Valovirta, Erkka Vasankari, Tuula Ventura, Maria-Teresa Walker, Samantha Williams, Sian Akdis, Cezmi A. and Annesi-Maesano, Isabella Arnavielhe, Sylvie Basagana, Xavier and Bateman, Eric Bedbrook, Anna Bennoor, K. S. Benveniste, Samuel Bergmann, Karl C. Bia, Slawomir Billo, Nils and Bindslev-Jensen, Carsten Bjermer, Leif Blain, Hubert Bonini, Mateo Bonniaud, Philippe Bouchard, Jacques Briedis, Vitalis and Brightling, Christofer E. Brozek, Jan Buhl, Roland and Buonaiuto, Roland Canonica, Giorgo W. Cardona, Victoria and Carriazo, Ana M. Carr, Warner Cartier, Christine Casale, Thomas Cecchi, Lorenzo Cepeda Sarabia, Alfonso M. and Chkhartishvili, Eka Chu, Derek K. Cingi, Cemal Colgan, Elaine de Sousa, Jaime Correia Courbis, Anne Lise Custovic, Adnan Cvetkosvki, Biljana D'Amato, Gennaro da Silva, Jane and Dantas, Carina Dokic, Dejand Dauvilliers, Yves Dedeu, Antoni De Feo, Giulia Devillier, Philippe Di Capua, Stefania and Dykewickz, Marc Dubakiene, Ruta Ebisawa, Motohiro and El-Gamal, Yaya Eller, Esben Emuzyte, Regina Farrell, John and Fink-Wagner, Antjie Fiocchi, Alessandro Fontaine, Jean F. and Gemicioglu, Bilun Schmid-Grendelmeir, Peter Gamkrelidze, Amiran Garcia-Aymerich, Judith Gomez, Maximiliano Gonzalez Diaz, Sandra Gotua, Maia Guldemond, Nick A. Guzman, Maria-Antonieta Hajjam, Jawad Hourihane, John O'B Humbert, Marc Iaccarino, Guido Ierodiakonou, Despo Ivancevich, Juan C. Joos, Guy Jung, Ki-Suck Jutel, Marek Kaidashev, Igor and Kalayci, Omer Kardas, Przemyslaw Keil, Thomas Khaitov, Mussa Khaltaev, Nikolai Kleine-Tebbe, Jorg Kowalski, Marek L. Kritikos, Vicky Kull, Inger Leonardini, Lisa and Lieberman, Philip Lipworth, Brian Carlsen, Karin C. Lodrup and Loureiro, Claudia C. Louis, Renaud Mair, Alpana Marien, Gert and Mahboub, Bassam Malva, Joao Manning, Patrick Keenoy, Esteban De Manuel Marshall, Gallen D. Masjedi, Mohamed R. and Maspero, Jorge F. Mathieu-Dupas, Eve Matricardi, Poalo M. and Melen, Eric Melo-Gomes, Elisabete Meltzer, Eli O. Mercier, Jacques Miculinic, Neven Mihaltan, Florin Milenkovic, Branislava Moda, Giuliana Mogica-Martinezl, Maria-Dolores and Mohammad, Yousser Montefort, Steve Monti, Ricardo and Morais-Almeida, Mario Moesges, Raft Munter, Lars Muraro, Antonella Murray, Ruth Naclerio, Robert Napoli, Luigi and Namazova-Baranova, Leila Neffen, Hugo Nekam, Kristoff Neou, Angelo Novellino, Enrico Nyembue, Dieudonne O'Hehir, Robin and Ohta, Ken Okubo, Kimi Onorato, Gabrielle Ouedraogo, Solange Pali-Schoell, Isabella Palkonen, Susanna Panzner, Peter Park, Hae-Sim Pepin, Jean-Louis Pereira, Ana-Maria and Pfaar, Oliver Paulino, Ema Phillips, Jim Plavec, Davor and Popov, Ted A. Portejoie, Fabienne Price, David Prokopakis, Emmanuel P. Pugin, Benoit Raciborski, Filip and Rajabian-Soderlund, Rojin Reitsma, Sietze Rodo, Xavier and Romano, Antonino Rosario, Nelson Rottem, Menahenm Ryan, Dermot Salimaki, Johanna Sanchez-Borges, Mario M. Sisul, Juan-Carlos Sole, Dirceu Somekh, David Sooronbaev, Talant and Sova, Milan Spranger, Otto Stellato, Cristina Stelmach, Rafael Ulrik, Charlotte Suppli Thibaudon, Michel To, Teresa and Todo-Bom, Ana Tomazic, V, Peter Valero, Antonio A. and Valenta, Rudolph Valentin-Rostan, Marylin van der Kleij, Rianne and Vandenplas, Olivier Vezzani, Giorgio Viart, Frederic and Vieg, Giovanni Wallace, Dana Wagenmann, Martin Wang, De Y. and Waserman, Susan Wickman, Magnus Williams, Dennis M. and Wong, Gary Wroczynski, Piotr Yiallouros, Panayiotis K. and Yorgancioglu, Arzu Yusuf, Osman M. Zar, Heahter J. Zeng, Stephane Zernotti, Mario Zhang, Luo Zhong, Nan S. and Zidarn, Mihaela ARIA Study Grp MASK Study Grp
Abstract: Background In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted “patient activation”, (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Sante as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement.
Published: 2019

44. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age

Author: Ferguson, Gary T, Karpel, Jill P, Clerisme-Beaty, Emmanuelle, Grönke, Lars, Voß, Florian, and Buhl, Roland
Subjects: Adult, Male, Time Factors, Health Status, Severity of Illness Index, Cholinergic Antagonists, FEV1, Pulmonary Disease, Chronic Obstructive, TDI, Forced Expiratory Volume, Humans, Multicenter Studies as Topic, Tiotropium Bromide, Adrenergic beta-2 Receptor Agonists, Lung, Original Research, Aged, Randomized Controlled Trials as Topic, Aged, 80 and over, SGRQ, Age Factors, lung function, Recovery of Function, Middle Aged, respiratory tract diseases, Benzoxazines, Bronchodilator Agents, Drug Combinations, Treatment Outcome, Clinical Trials, Phase III as Topic, rescue medication
Abstract: Background Increasing age is associated with poor prognosis in patients with COPD. Objective This analysis from the replicate Phase III OTEMTO® and TONADO® studies examined the efficacy and safety of tiotropium, a long-acting anticholinergic, combined with olodaterol, a long-acting β2-agonist, compared to monotherapies and placebo in patients with COPD aged 40 years to
Published: 2016

45. Serum eosinophil cationic protein as a potential biomarker for interleukin-5 antibody treatment in patients with severe uncontrolled eosinophilic asthma

Author: Korn Stephanie, Buhl Roland, and Maike Wilk
Subjects: Spirometry, medicine.medical_specialty, biology, medicine.diagnostic_test, business.industry, Physical examination, medicine.disease, Gastroenterology, Internal medicine, Concomitant, medicine, biology.protein, Medical history, Antibody, business, Interleukin 5, Mepolizumab, Asthma, medicine.drug
Abstract: Serum eosinophil cationic protein (ECP) has been described as a marker reflecting activation of eosinophils in asthma, potentially correlating to airway inflammation. Our aim was to examine the role of serum ECP to predict treatment efficacy in asthmatics starting interleukin-5 antibody (anti-IL5) therapy. We evaluated 65 patients with severe, uncontrolled eosinophilic asthma (≥300 eosinophils per µl blood) before and approx. 4 months after initiation of anti-IL5 therapy with mepolizumab; 35 patients completed a 12 month follow-up. Evaluation of treatment efficacy included medical history, asthma questionnaires, physical examination, spirometry, exhaled NO and blood tests. Depending on the results, patients were grouped into treatment responders and non-responders. 65% (n=42) of our patients had elevated ECP levels (> 20 ng/ml) before anti-IL5 therapy. After 4 and 12 months ECP was normal in 80% and 82% of patients. 7 patients (11%) were counted as non-responders after 4 months, 2 patients experienced a loss of response between the 4 and 12 month evaluation. 22 patients with normal ECP values before therapy responded to treatment. In summary, the majority of patients with severe uncontrolled eosinophilic asthma had elevated serum ECP levels before initiation of anti-IL5 treatment, which decreased or normalized during therapy, irrespective of treatment response. Interestingly, a group of patients with normal ECP values before therapy still had a benefit from treatment. Further research will be conducted to evaluate possible confounders such as concomitant medication.
Published: 2018

46. New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology

Author: D'Urzo,Anthony, Cazzola,Mario, Hanania,Nicola, Buhl,Roland, and Maleki-Yazdi,M. Reza
Subjects: International Journal of Chronic Obstructive Pulmonary Disease
Abstract: Anthony D D’Urzo,1 Mario Cazzola,2 Nicola A Hanania,3 Roland Buhl,4 M Reza Maleki-Yazdi5 1Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 2Department of Experimental Medicine and Surgery, Tor Vergata University of Rome, Rome, Italy; 3Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA; 4Pulmonary Department, Mainz University Hospital, Mainz, Germany; 5Division of Respiratory Medicine, Women’s College Hospital, University of Toronto, Toronto, ON, Canada Abstract: COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are central to the maintenance treatment of patients with COPD. Clinical studies have demonstrated that combined LAMA + LABA therapies improve efficacy while retaining a safety profile similar to LAMA or LABA alone. This has led to the development of several LAMA/LABA fixed-dose combination (FDC) therapies, which provide patients with the convenience of two active compounds in a single inhaler. GFF MDI (Bevespi Aerosphere®) is an FDC of glycopyrrolate/formoterol fumarate 18/9.6 µg formulated using innovative co-suspension delivery technology for administration via metered dose inhaler (MDI). GFF MDI was developed to make a treatment option available for patients who have a requirement or preference to use an MDI, rather than a dry powder or soft mist inhaler. Now that several LAMA/LABA FDCs have been approved for use in COPD, we review the impact of dual-bronchodilator treatment on COPD therapy and discuss recent clinical studies that are helping to develop a more comprehensive understanding of how LAMA/LABA FDCs can improve patient outcomes. Keywords: long-acting bronchodilator, LAMA, LABA, chronic obstructive pulmonary disease, fixed-dose combination, GFF MDI
Published: 2018

47. Dual bronchodilation vs triple therapy in the 'real-life' COPD DACCORD study

Author: Buhl, Roland, Criée, Carl-Peter, Kardos, Peter, Vogelmeier, Claus F., Kostikas, Konstantinos, Lossi, Nadine S., Worth, Heinrich, and Russell, Richard
Subjects: ddc:610
Abstract: Background: No observational studies have evaluated the "real-world" effectiveness of dual bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic antagonist vs that of triple therapy (long-acting β2-agonist plus long-acting muscarinic antagonist plus inhaled corticosteroid) in COPD. Materials and methods: DACCORD is a non-interventional, observational clinical study that recruited patients following COPD maintenance therapy initiation or change in maintenance therapy between or within therapeutic class. Given the non-interventional nature of the study, the decision to initiate or change medication had to be made by the patients’ physicians prior to inclusion in DACCORD. We used a matched-pairs analysis to compare disease progression in two patient groups: those receiving dual bronchodilation vs those receiving triple therapy (each group n=1,046). Results: In two subgroups of patients matched according to a broad range of demographic and disease characteristics, over 1 year, fewer patients receiving dual bronchodilation exacerbated than those receiving triple therapy (15.5% vs 26.6%; P
Published: 2018

48. Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies

Author: LaForce,Craig, Derom,Eric, Bothner,Ulrich, Kloer,Isabel, Trampisch,Matthias, and Buhl,Roland
Subjects: International Journal of Chronic Obstructive Pulmonary Disease, humanities
Abstract: Craig LaForce,1 Eric Derom,2 Ulrich Bothner,3 Isabel M Kloer,3 Matthias Trampisch,4 Roland Buhl5 1NC Clinical Research, Raleigh, NC, USA; 2Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; 3Pharmacovigilance, Boehringer Ingelheim International GmbH, Ingelheim, Germany; 4Biostatistics & Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 5Pulmonary Department, Mainz University Hospital, Mainz, Germany Introduction: The safety, lung function efficacy, and symptomatic benefits of combined tiotropium and olodaterol in patients with COPD were established in the 1-year TONADO® studies (NCT01431274; NCT01431287). As tiotropium is predominantly excreted by the kidneys, the long-term safety profile of tiotropium/olodaterol was investigated in patients with renal impairment in a prespecified safety analysis of the TONADO studies. Methods: These were 2 replicate, randomized, double-blind, parallel-group, 52-week Phase III studies that assessed tiotropium/olodaterol compared with tiotropium or olodaterol alone (all via Respimat®) in patients with moderate-to-very severe COPD. In this analysis, renal impairment was defined as mild (creatinine clearance [CLcr] 60–89 mL/min), moderate (CLcr 30–59 mL/min) or severe (CLcr 15–29 mL/min). Adverse events (AEs) were pooled from both studies. Results: Of 3,041 patients included in this analysis, 1,333 (43.8%) had mild, 404 (13.3%) had moderate, and 5 (0.2%) had severe renal impairment; these were distributed equally between treatment groups. Almost one-quarter of all treated patients (23.4%) had a history of cardiac disorder, 45.6% had hypertension, and 13.3% had glucose metabolism disorders, including diabetes. AEs with olodaterol, tiotropium, and tiotropium/olodaterol occurred in 75.1%, 70.8%, and 72.0% of patients with no renal impairment, 75.7%, 74.0%, and 73.3% with mild renal impairment, and 84.3%, 79.5%, and 79.7% with moderate renal impairment, respectively. There was no notable effect of renal impairment on the proportion of patients with an AE, and no differences were observed between tiotropium/olodaterol versus the monocomponents. There was no difference in the incidence of major adverse cardiac events, renal and urinary tract AEs, or potential anticholinergic effects with increasing severity of renal impairment. Conclusion: Over half the patients enrolled in the TONADO studies had renal impairment, and there was a high level of pre-existing cardiovascular comorbidity. The safety and tolerability of tiotropium/olodaterol is comparable to the monocomponents, irrespective of the level of renal impairment. Keywords: COPD, renal impairment, comorbidities, tiotropium, olodaterol, safety
Published: 2018

49. Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies

Author: LaForce, Craig, Derom, Eric, Bothner, Ulrich, Kloer, Isabel M, Trampisch, Matthias, and Buhl, Roland
Subjects: renal impairment, safety, PHARMACOKINETICS, SERUM CREATININE, olodaterol, comorbidities, OPEN-LABEL, GOLD 2-4, OBSTRUCTIVE PULMONARY-DISEASE, tiotropium, Medicine and Health Sciences, COPD, TRIAL, FIXED-DOSE COMBINATION, ACUTE URINARY RETENTION
Abstract: Introduction: The safety, lung function efficacy, and symptomatic benefits of combined tiotropium and olodaterol in patients with COPD were established in the 1-year TONADO (R) studies (NCT01431274; NCT01431287). As tiotropium is predominantly excreted by the kidneys, the long-term safety profile of tiotropium/olodaterol was investigated in patients with renal impairment in a prespecified safety analysis of the TONADO studies. Methods: These were 2 replicate, randomized, double-blind, parallel-group, 52-week Phase III studies that assessed tiotropium/olodaterol compared with tiotropium or olodaterol alone (all via Respimat (R)) in patients with moderate-to-very severe COPD. In this analysis, renal impairment was defined as mild (creatinine clearance [CLcr] 60-89 mL/min), moderate (CLcr 30-59 mL/min) or severe (CLcr 15-29 mL/min). Adverse events (AEs) were pooled from both studies. Results: Of 3,041 patients included in this analysis, 1,333 (43.8%) had mild, 404 (13.3%) had moderate, and 5 (0.2%) had severe renal impairment; these were distributed equally between treatment groups. Almost one-quarter of all treated patients (23.4%) had a history of cardiac disorder, 45.6% had hypertension, and 13.3% had glucose metabolism disorders, including diabetes. AEs with olodaterol, tiotropium, and tiotropium/olodaterol occurred in 75.1%, 70.8%, and 72.0% of patients with no renal impairment, 75.7%, 74.0%, and 73.3% with mild renal impairment, and 84.3%, 79.5%, and 79.7% with moderate renal impairment, respectively. There was no notable effect of renal impairment on the proportion of patients with an AE, and no differences were observed between tiotropium/olodaterol versus the monocomponents. There was no difference in the incidence of major adverse cardiac events, renal and urinary tract AEs, or potential anticholinergic effects with increasing severity of renal impairment. Conclusion: Over half the patients enrolled in the TONADO studies had renal impairment, and there was a high level of pre-existing cardiovascular comorbidity. The safety and tolerability of tiotropium/olodaterol is comparable to the monocomponents, irrespective of the level of renal impairment.
Published: 2018

50. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases

Author: Pfaar, Oliver, Bachert, Claus, Bufe, Albrecht, Buhl, Roland, Ebner, Christof, Eng, Peter, Friedrichs, Frank, Fuchs, Thomas, Hamelmann, Eckard, Hartwig-Bade, Doris, Hering, Thomas, Huttegger, Isidor, Jung, Kirsten, Klimek, Ludger, Kopp, Matthias Volkmar, Merk, Hans, Rabe, Uta, Saloga, Joachim, Schmid-Grendelmeier, Peter, Schuster, Antje, Schwerk, Nicolaus, Sitter, Helmut, Umpfenbach, Ulrich, Wedi, Bettina, Wöhrl, Stefan, Worm, Margitta, Kleine-Tebbe, Jörg, Kaul, Susanne, and Schwalfenberg, Anja
Subjects: Hyposensitization, allergic disease, allergic rhinitis, allergen extract, AIT, Guideline_AIT-Guideline, allergen-specific immunotherapy, guideline, allergic asthma, allergen
Abstract: Summary The present guideline (S2k) on allergen-specific immunotherapy (AIT) was established by the German, Austrian and Swiss professional associations for allergy in consensus with the scientific specialist societies and professional associations in the fields of otolaryngology, dermatology and venereology, pediatric and adolescent medicine, pneumology as well as a German patient organization (German Allergy and Asthma Association; Deutscher Allergie- und Asthmabund, DAAB) according to the criteria of the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF). AIT is a therapy with disease-modifying effects. By administering allergen extracts, specific blocking antibodies, toler-ance-inducing cells and mediators are activated. These prevent further exacerbation of the allergen-triggered immune response, block the specific immune response and attenuate the inflammatory response in tissue. Products for SCIT or SLIT cannot be compared at present due to their heterogeneous composition, nor can allergen concentrations given by different manufacturers be compared meaningfully due to the varying methods used to measure their active ingredients. Non-modified allergens are used for SCIT in the form of aqueous or physically adsorbed (depot) extracts, as well as chemically modified allergens (allergoids) as depot extracts. Allergen extracts for SLIT are used in the form of aqueous solutions or tablets. The clinical efficacy of AIT is measured using various scores as primary and secondary study endpoints. The EMA stipulates combined symptom and medication scores as primary endpoint. A harmonization of clinical endpoints, e. g., by using the combined symptom and medication scores (CSMS) recommended by the EAACI, is desirable in the future in order to permit the comparison of results from different studies. The current CONSORT recommendations from the ARIA/GA2LEN group specify standards for the evaluation, presentation and publication of study results. According to the Therapy allergen ordinance (TAV), preparations containing common allergen sources (pollen from grasses, birch, alder, hazel, house dust mites, as well as bee and wasp venom) need a marketing authorization in Germany. During the marketing authorization process, these preparations are examined regarding quality, safety and efficacy. In the opinion of the authors, authorized allergen preparations with documented efficacy and safety, or preparations tradeable under the TAV for which efficacy and safety have already been documented in clinical trials meeting WAO or EMA standards, should be preferentially used. Individual formulations (NPP) enable the prescription of rare allergen sources (e.g., pollen from ash, mugwort or ambrosia, mold Alternaria, animal allergens) for specific immunotherapy. Mixing these allergens with TAV allergens is not permitted. Allergic rhinitis and its associated co-morbidities (e. g., bronchial asthma) generate substantial direct and indirect costs. Treatment options, in particular AIT, are therefore evaluated using cost-benefit and cost-effectiveness analyses. From a long-term perspective, AIT is considered to be significantly more cost effective in allergic rhinitis and allergic asthma than pharmacotherapy, but is heavily dependent on patient compliance. Meta-analyses provide unequivocal evidence of the efficacy of SCIT and SLIT for certain allergen sources and age groups. Data from controlled studies differ in terms of scope, quality and dosing regimens and require product-specific evaluation. Therefore, evaluating individual preparations according to clearly defined criteria is recommended. A broad transfer of the efficacy of certain preparations to all preparations administered in the same way is not endorsed. The website of the German Society for Allergology and Clinical Immunology (www.dgaki.de/leitlinien/s2k-leitlinie-sit; DGAKI: Deutsche Gesellschaft für Allergologie und klinische Immunologie) provides tables with specific information on available products for AIT in Germany, Switzerland and Austria. The tables contain the number of clinical studies per product in adults and children, the year of market authorization, underlying scoring systems, number of randomized and analyzed subjects and the method of evaluation (ITT, FAS, PP), separately given for grass pollen, birch pollen and house dust mite allergens, and the status of approval for the conduct of clinical studies with these products. Strong evidence of the efficacy of SCIT in pollen allergy-induced allergic rhinoconjunctivitis in adulthood is well-documented in numerous trials and, in childhood and adolescence, in a few trials. Efficacy in house dust mite allergy is documented by a number of controlled trials in adults and few controlled trials in children. Only a few controlled trials, independent of age, are available for mold allergy (in particular Alternaria). With regard to animal dander allergies (primarily to cat allergens), only small studies, some with methodological deficiencies are available. Only a moderate and inconsistent therapeutic effect in atopic dermatitis has been observed in the quite heterogeneous studies conducted to date. SCIT has been well investigated for individual preparations in controlled bronchial asthma as defined by the Global Initiative for Asthma (GINA) 2007 and intermittent and mild persistent asthma (GINA 2005) and it is recommended as a treatment option, in addition to allergen avoidance and pharmacotherapy, provided there is a clear causal link between respiratory symptoms and the relevant allergen. The efficacy of SLIT in grass pollen-induced allergic rhinoconjunctivitis is extensively documented in adults and children, whilst its efficacy in tree pollen allergy has only been shown in adults. New controlled trials (some with high patient numbers) on house dust mite allergy provide evidence of efficacy of SLIT in adults. Compared with allergic rhinoconjunctivitis, there are only few studies on the efficacy of SLIT in allergic asthma. In this context, newer studies show an efficacy for SLIT on asthma symptoms in the subgroup of grass pollen allergic children, adolescents and adults with asthma and efficacy in primary house dust mite allergy-induced asthma in adolescents aged from 14 years and in adults. Aspects of secondary prevention, in particular the reduction of new sensitizations and reduced asthma risk, are important rationales for choosing to initiate treatment early in childhood and adolescence. In this context, those products for which the appropriate effects have been demonstrated should be considered. SCIT or SLIT with pollen or mite allergens can be performed in patients with allergic rhinoconjunctivitis using allergen extracts that have been proven to be effective in at least one double-blind placebo-controlled (DBPC) study. At present, clinical trials are underway for the indication in asthma due to house dust mite allergy, some of the results of which have already been published, whilst others are still awaited (see the DGAKI table “Approved/potentially completed studies” via www.dgaki.de/Leitlinien/s2k-Leitlinie-sit (according to www.clinicaltrialsregister.eu)). When establishing the indication for AIT, factors that favour clinical efficacy should be taken into consideration. Differences between SCIT and SLIT are to be considered primarily in terms of contraindications. In individual cases, AIT may be justifiably indicated despite the presence of contraindications. SCIT injections and the initiation of SLIT are performed by a physician experienced in this type of treatment and who is able to administer emergency treatment in the case of an allergic reaction. Patients must be fully informed about the procedure and risks of possible adverse events, and the details of this process must be documented (see “Treatment information sheet”; available as a handout via www.dgaki.de/Leitlinien/s2k-Leitlinie-sit). Treatment should be performed according to the manufacturer‘s product information leaflet. In cases where AIT is to be performed or continued by a different physician to the one who established the indication, close cooperation is required in order to ensure that treatment is implemented consistently and at low risk. In general, it is recommended that SCIT and SLIT should only be performed using preparations for which adequate proof of efficacy is available from clinical trials. Treatment adherence among AIT patients is lower than assumed by physicians, irrespective of the form of administration. Clearly, adherence is of vital importance for treatment success. Improving AIT adherence is one of the most important future goals, in order to ensure efficacy of the therapy. Severe, potentially life-threatening systemic reactions during SCIT are possible, but – providing all safety measures are adhered to – these events are very rare. Most adverse events are mild to moderate and can be treated well. Dose-dependent adverse local reactions occur frequently in the mouth and throat in SLIT. Systemic reactions have been described in SLIT, but are seen far less often than with SCIT. In terms of anaphylaxis and other severe systemic reactions, SLIT has a better safety profile than SCIT. The risk and effects of adverse systemic reactions in the setting of AIT can be effectively reduced by training of personnel, adhering to safety standards and prompt use of emergency measures, including early administration of i. m. epinephrine. Details on the acute management of anaphylactic reactions can be found in the current S2 guideline on anaphylaxis issued by the AWMF (S2-AWMF-LL Registry Number 061-025). AIT is undergoing some innovative developments in many areas (e. g., allergen characterization, new administration routes, adjuvants, faster and safer dose escalation protocols), some of which are already being investigated in clinical trials. Cite this as Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, Friedrichs F, Fuchs T, Hamelmann E, Hartwig-Bade D, Hering T, Huttegger I, Jung K, Klimek L, Kopp MV, Merk H, Rabe U, Saloga J, Schmid-Grendelmeier P, Schuster A, Schwerk N, Sitter H, Umpfenbach U, Wedi B, Wöhrl S, Worm M, Kleine-Tebbe J. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases – S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int 2014;23:282–319
Published: 2014

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

60 results on '"Buhl Roland"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources